A Phase I Dose Escalation Study of Topical Bexarotene in Women at High Risk for Breast Cancer
Phase: PHASE1
Conditions: Breast Atypical Ductal Hyperplasia, Breast Atypical Lobular Hyperplasia, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ, Invasive Breast Carcinoma
Sponsor: National Cancer Institute (NCI)

DCP Protocol Number MDA2016-08-02 
Protocol Version 14, Dated 4/27/2021 
 
DCP Protocol Template Version 8.5 
–1– 
08/31/2016 
 
 
COVER PAGE 
 
 
 
 
 
DCP Protocol #: 
MDA2016-08-02 
 
Local Protocol #: 2017-0911 
 
A Phase I Dose Escalation Study of Topical Bexarotene in Women at High Risk for Breast Cancer 
 
 
Consortium Name: 
 
University of Texas MD Anderson Early Phase Clinical Research 
Consortium 
Name of Consortium Principal  
Powel H. Brown, MD, PhD 
Investigator: 
 
Professor and Chair, Department of Clinical Cancer Prevention 
 
 
University of Texas MD Anderson Cancer Center 
 
 
1515 Holcombe Boulevard, Unit 1360 
Houston, TX 77030-4009 
Telephone: (713) 792-4509 
Fax: (713) 794-4679 
 
 
phbrown@mdanderson.org 
 
MD Anderson Consortium 
 
Lana A. Vornik, MHA, MS 
Administrative Director: 
 
Associate Director, Research Planning and Development 
 
 
Department of Clinical Cancer Prevention 
 
 
University of Texas MD Anderson Cancer Center 
 
 
1515 Holcombe Boulevard, Unit 1360 
Houston, TX 77030-4009 
Telephone: (713) 792-9594 
Fax: (713) 745-4230 
 
 
lavornik@mdanderson.org 
 
MD Anderson Consortium 
 
Saba Abutaseh, BS 
Lead Org Coordinator: 
 
CLO Coordinator 
 
 
Department of Clinical Cancer Prevention 
 
 
University of Texas MD Anderson Cancer Center 
 
 
1515 Holcombe Boulevard, Unit 1360 
Houston, TX 77030-4009 
Telephone: 713-745-8181 
Fax: (713) 745-4230 
 
 
sgabutas@mdanderson.org 
 
 
Organization Name: 
 
 
University of Texas MD Anderson Cancer Center  
Protocol Principal Investigator: 
Parijatham Thomas, M.D. 
Assistant Professor 
Department of Clinical Cancer Prevention 
1515 Holcombe Blvd. 
Unit 1360 
Houston, TX  77030 
Telephone: (713) 745-1075 
Fax: (713) 794-4403 

DCP Protocol Number MDA2016-08-02 
Protocol Version 14, Dated 4/27/2021 
 
DCP Protocol Template Version 8.5 
–2– 
08/31/2016 
 
psthomas@mdanderson.org 
 
Organization Name: 
 
 
University of Texas MD Anderson Cancer Center  
Co-Principal Investigator: 
Anisha B. Patel, M.D. 
Assistant Professor 
Department of Dermatology 
1515 Holcombe Blvd. 
Unit 1452 
Houston, TX  77030 
Telephone: 713-745-4615 
APatel11@mdanderson.org 
 
 
Organization: 
 
University of Texas MD Anderson Cancer Center 
Lead Statistician: 
 
J. Jack Lee, Ph.D. 
 
 
1515 Holcombe Boulevard, Unit 447 
Houston, TX 77230 
 
 
Telephone: (713) 794-4158 
 
 
Fax: (713) 563-4242 
 
 
 
    
       jjlee@mdanderson.org 
 
Organization: 
 
University of Texas MD Anderson Cancer Center 
Protocol Statistician: 
 
Diane Liu 
 
 
1515 Holcombe Boulevard, Unit 447 
Houston, TX 77230 
 
 
Telephone: (713) 794-4175 
 
 
Fax: (713) 563-4242 
dianeliu@mdanderson.org 
 
Organization: 
 
Northwestern University 
Consultant: 
 
Seema Khan, MD 
 
 
 
 
      Department of Surgery 
      303 East Superior Street 
      Chicago, IL 60611 
      (312)503-4236 office 
      (312)503-2555 fax 
 
      s-khan2@northwestern.edu 
 
 
Medical Monitor 
 
Marjorie Perloff, MD 
Chemopreventive Agent Development Research Group 
Division of Cancer Prevention 
9609 Medical, Rm 5E544 
Rockville, MD 200850 
Office Tel (240)276-7097 
Cell (240)731-1772 
FAX (240)276-7847 
Email: perloffm@mail.nih.gov 
 
 
 
 

DCP Protocol Number MDA2016-08-02 
Protocol Version 14, Dated 4/27/2021 
 
DCP Protocol Template Version 8.5 
–3– 
08/31/2016 
 
 
 
Scientific Monitor: 
 
Brandy Heckman-Stoddard, PhD, MPH 
 
 
Breast and Gynecologic Cancer Research Group 
 
 
Division of Cancer Prevention 
 
 
9609 Medical Center Dr. 
 
 
Bethesda, MD 20892-9783 
 
 
Phone number: (240)276-7048 
 
 
Fax number: (240)276-7828 
 
 
Email: heckmanbm@mail.nih.gov 
 
 
IND Sponsor:  
NCI DCP 
 
IND#  
 
Exempt 
 
Agent(s)/Supplier: 
Targretin® (bexarotene) gel 1% / Valeant Pharmaceuticals 
 
NCI Contract # 
 HHSN261201200034I 
 
Protocol Version Date:  4/27/2021 
 
Protocol Revision or   
Amendment #  
Version 14 
 

DCP Protocol Number MDA2016-08-02 
Protocol Version 14, Dated 4/27/2021 
 
DCP Protocol Template Version 8.5 
–4– 
08/31/2016 
 
SCHEMA 
A Phase I Dose Escalation Study of Topical Bexarotene in Women at High Risk for Breast Cancer 
 
Part 1: Dose Escalation Group 
Screening/Baseline Clinic Visit Day -30 to 0 
Women with ADH, ALH, LCIS, Breast cancer survivors (DCIS or invasive) ≥ 5 years from their diagnosis, BRCA 1/2 
mutation carriers, or elevated risk for breast cancer ≥1.7% in 5 years or lifetime risk ≥20%  
 
Intervention (N=30) Dose Assignment by a 3+3 dose escalation with 3 dose levels (Day 0): 
Bexarotene 1% gel 10mg/breast/every other day or Bexarotene 1% gel 10mg/breast/daily or  
Bexarotene 1% gel 20mg/breast/daily for treatment duration of 4 weeks 
 
Start Treatment (Day 1) 
 
Phone Call (Day 8)  
Assess AEs and review Gel Diary 
 
Study Visits (Day 15 and Day 28 (End of Study)) 
Assess for AEs & review gel diary. Labs to assess safety (CBC, LFTs, Lipid Profile, Thyroid Function Tests, Calcium) 
on Day 15 and 28 visits. Serum bexarotene collected on Day 0 and Day 28 visit. Optional breast biopsy at Day 28 visit. 
 
Follow Up Call (30 days ± 7 days after Day 28) 
Assess for any further AE and document resolution of any acquired AE during treatment 
 
Primary Endpoint: Safety and Toxicity 
Secondary Endpoints: Serum and Tissue Bexarotene level, calcium, lipid and thyroid function biomarkers  
 
Part 2: Dose Expansion Group 
Screening/Baseline Clinic Visit Day -30 to 0 
Women with ADH, ALH, LCIS, Breast cancer survivors (DCIS or invasive) that are ≥ 5 years from their diagnosis, 
BRCA 1/2 mutation carriers, or elevated risk for breast cancer ≥1.7% in 5 years or lifetime risk ≥20%  
 
Intervention (N=10) (Day 0): 
Bexarotene 1% gel at maximum tolerated dose from Part A Dose Escalation Group for 4 weeks.  
 
Start Treatment (Day 1) 
Start application of bexarotene gel to one unaffected breast  
 
Phone Call (Day 8)  
Assess adverse events and review Gel Diary 
 
Study Visits (Day 15 and Day 28 (End of Study)) 
Assess for AEs & review gel diary. Labs to assess safety (CBC, LFTs, Lipid Profile, Thyroid Function Tests, Calcium) 
on Day 15 and 28 visits. Serum bexarotene collected on Day 28 visit. Mandatory breast biopsy at Day 28 visit. 
 
Primary Endpoint: Safety and Toxicity 
Secondary Endpoints: Serum and Tissue Bexarotene level, calcium, lipid and thyroid function biomarkers 
 
Follow Up Call (30 days ± 7 days after Day 28) 
Assess for any further AE and document resolution of any acquired AE during treatment 

DCP Protocol Number MDA2016-08-02 
Protocol Version 14, Dated 4/27/2021 
 
DCP Protocol Template Version 8.5 
–5– 
08/31/2016 
 
TABLE OF CONTENTS 
 
COVER PAGE ........................................................................................................................................ 1 
SCHEMA ................................................................................................................................................ 4 
1. 
OBJECTIVES ................................................................................................................................ 7 
1.1 
Primary Objectives .................................................................................................................. 7 
1.2 
Secondary Objectives .............................................................................................................. 7 
2. 
BACKGROUND ........................................................................................................................... 7 
2.1 
Breast Cancer Prevention ......................................................................................................... 7 
2.2 
Bexarotene .............................................................................................................................. 7 
2.3 
Rationale ................................................................................................................................. 8 
3. 
SUMMARY OF STUDY PLAN .................................................................................................. 10 
4. 
PARTICIPANT SELECTION...................................................................................................... 11 
4.1 
Inclusion Criteria ................................................................................................................... 11 
4.2 
Exclusion Criteria .................................................................................................................. 12 
4.3 
Inclusion of Women and Minorities ....................................................................................... 12 
4.4 
Recruitment and Retention Plan ............................................................................................. 12 
5. 
AGENT ADMINISTRATION ..................................................................................................... 13 
5.1 
Dose Regimen and Dose Groups/Gel Application .................................................................. 13 
5.2 
Gel Administration/Run-in Procedures ................................................................................... 14 
5.3 
Contraindications ................................................................................................................... 14 
5.4 
Concomitant Medications ...................................................................................................... 14 
5.5 
Dose Modification ................................................................................................................. 15 
5.6 
Adherence/Compliance .......................................................................................................... 16 
6. 
PHARMACEUTICAL INFORMATION ..................................................................................... 16 
6.1 
Bexarotene Gel (IND #, IND Sponsor) ................................................................................... 16 
6.2 
Reported Adverse Events and Potential Risks ........................................................................ 17 
6.3  Availability ............................................................................................................................ 18 
6.4 
Agent Distribution ................................................................................................................. 18 
6.5  Agent Accountability ............................................................................................................. 19 
6.6 
Packaging and Labeling ......................................................................................................... 19 
6.7 
Storage .................................................................................................................................. 19 
6.8 
Registration ........................................................................................................................... 20 
6.9 
Blinding and Unblinding Methods ......................................................................................... 20 
6.10 Agent Destruction/Disposal ................................................................................................... 20 
7. 
CLINICAL EVALUATIONS AND PROCEDURES ................................................................... 21 
7.1 
Schedule of Events ................................................................................................................ 21 
7.2 
Baseline Testing/Prestudy Evaluation .................................................................................... 22 
7.3 
Evaluation During Study Intervention .................................................................................... 24 
7.4 
Evaluation at Completion of Study Intervention ..................................................................... 24 
7.5 
Post-intervention Follow-up Period ........................................................................................ 25 
7.6 
Methods for Clinical Procedures ............................................................................................ 25 
8.  
CRITERIA FOR EVALUATION AND ENDPOINT DEFINITION ............................................ 25 
8.1 
Primary Endpoint ................................................................................................................... 25 
8.2 
Secondary Endpoints ............................................................................................................. 27 
8.3 
Off-Agent Criteria ................................................................................................................. 27 
8.4 
Off-Study Criteria .................................................................................................................. 27 
8.5 
Study Termination ................................................................................................................. 28 
9. 
CORRELATIVE/SPECIAL STUDIES ........................................................................................ 28 
9.1 
Rationale for Methodology Selection ..................................................................................... 28 
9.2 
Comparable Methods ............................................................................................................. 28 

DCP Protocol Number MDA2016-08-02 
Protocol Version 14, Dated 4/27/2021 
 
DCP Protocol Template Version 8.5 
–6– 
08/31/2016 
 
10. 
SPECIMEN MANAGEMENT ..................................................................................................... 28 
10.1 Laboratories........................................................................................................................... 28 
10.2 Collection and Handling Procedures ...................................................................................... 28 
10.3 Shipping Instructions ............................................................................................................. 29 
10.4 Tissue Banking ...................................................................................................................... 30 
11. 
REPORTING ADVERSE EVENTS............................................................................................. 30 
11.1 Adverse Events ...................................................................................................................... 30 
11.2 Serious Adverse Events ......................................................................................................... 32 
12. 
STUDY MONITORING .............................................................................................................. 33 
12.1 Data Management .................................................................................................................. 33 
12.2 Case Report Forms ................................................................................................................ 33 
12.3 Source Documents ................................................................................................................. 34 
12.4 Data and Safety Monitoring Plan ........................................................................................... 34 
12.5 Sponsor or FDA Monitoring .................................................................................................. 35 
12.6 Record Retention ................................................................................................................... 35 
12.7 Cooperative Research and Development Agreement (CRADA)/Clinical Trials Agreement (CTA) 35 
13. 
STATISTICAL CONSIDERATIONS .......................................................................................... 36 
13.1 Study Design/Description ...................................................................................................... 36 
13.2 Randomization/Stratification.................................................................................................. 37 
13.3 Accrual and Feasibility .......................................................................................................... 37 
13.4 Primary Objective, Endpoint(s), Analysis Plan ....................................................................... 37 
13.5 Secondary Objectives, Endpoints, Analysis Plans................................................................... 38 
13.6 Reporting and Exclusions ...................................................................................................... 38 
13.7 Evaluation of Toxicity ........................................................................................................... 39 
13.8 Evaluation of Response .......................................................................................................... 39 
13.9 Interim Analysis .................................................................................................................... 39 
13.10 Ancillary Studies ................................................................................................................... 39 
14. 
ETHICAL AND REGULATORY CONSIDERATIONS .............................................................. 39 
14.1 Form FDA 1572 .................................................................................................................... 39 
14.2 Other Required Documents .................................................................................................... 39 
14.3 Institutional Review Board Approval ..................................................................................... 40 
14.4 Informed Consent .................................................................................................................. 40 
14.5 Submission of Regulatory Documents .................................................................................... 41 
14.6 Other ..................................................................................................................................... 41 
15. 
FINANCING, EXPENSES, AND/OR INSURANCE ................................................................... 41 
REFERENCES...................................................................................................................................... 42 
APPENDIX A ....................................................................................................................................... 43 
APPENDIX B ....................................................................................................................................... 43 
APPENDIX C ....................................................................................................................................... 47 
APPENDIX D ....................................................................................................................................... 60 
APPENDIX E ....................................................................................................................................... 66 
APPENDIX F........................................................................................................................................ 71 
APPENDIX G ....................................................................................................................................... 74 

DCP Protocol Number MDA2016-08-02 
Protocol Version 14, Dated 4/27/2021 
 
DCP Protocol Template Version 8.5 
–7– 
08/31/2016 
 
1. 
OBJECTIVES 
 
The overall objective is to evaluate the safety and toxicity of topical bexarotene 1% gel to the breast in healthy 
women at high risk for breast cancer and bexarotene concentration in the breast tissue. 
 
 
1.1 
Primary Objectives  
 
A. Dose Escalation Group  
 
We will conduct a trial to determine the recommended phase II dose of topical bexarotene 1% (w/w) gel for 
evaluation in healthy women. This will be determined by assessing the safety and toxicity of topical bexarotene 
gel application (tested at three different dose levels by dose escalation, 10 mg (1 mL) every other day, 
10 mg (1 mL) daily, or 20 mg (2 mL) daily to an unaffected breast of healthy women at high risk for breast 
cancer for a duration of 4 weeks. 
 
B. Dose Expansion Group 
 
We will conduct an intervention of topical 1% bexarotene gel to an unaffected breast of healthy women at high 
risk for breast cancer for 4 weeks at the maximum tolerated dose (MTD) as determined during the dose 
escalation group phase to assess bexarotene concentration in the breast tissue. 
 
 
1.2 
Secondary Objectives  
1. To detect bexarotene concentration in the serum at baseline and at 4 weeks of treatment. 
2. To detect bexarotene concentration in the breast tissue at 4 weeks of treatment in the dose escalation 
group. 
3. To investigate the effects of topical bexarotene on serum biomarkers we will determine the change 
from the baseline in:  
i. Lipid Biomarkers (Total Cholesterol, triglycerides, LDL, HDL) 
ii. Thyroid Function Biomarkers (Thyroid Stimulating Hormone (TSH), T4, T3) 
iii. Calcium 
 
1.3 
Exploratory Objective (Dose Expansion Group) 
 
To examine changes in gene expression associated with retinoid action. 
 
2. 
BACKGROUND 
 
2.1 
Breast Cancer Prevention 
 
Breast cancer is the most common malignancy among women in the US, and prevention of this disease is 
therefore a major public health concern. Chemoprevention with anti-estrogens, including tamoxifen, raloxifene, 
and exemestane, has been shown to reduce the incidence of hormone receptor (HR)-positive breast cancer. 
However, agents that can reduce the incidence of hormone receptor negative breast cancer are currently lacking.  
 
2.2 
Bexarotene  
 
Retinoids are vitamin A analogues that have been shown to be involved in cell differentiation, growth, and 
apoptosis (1). They exert their effects by binding to two specific classes of receptors known as the retinoic acid 
receptors (RAR) and retinoic X receptors (RXR).  Once activated, RARs and RXRs form heterodimers and 
function as transcription factors and subsequently bind to retinoic acid response elements (RARE) and regulate 

DCP Protocol Number MDA2016-08-02 
Protocol Version 14, Dated 4/27/2021 
 
DCP Protocol Template Version 8.5 
–8– 
08/31/2016 
 
gene expression regulating cell differentiation, growth, and apoptosis (2, 3). Rexinoids are similar agents but 
only activate the RXR receptors without activating the RAR nuclear receptors. Bexarotene is a rexinoid that 
has been studied extensively and is currently an FDA approved treatment for cutaneous T cell lymphoma 
(CTCL). 
 
Oral bexarotene was evaluated in phase 2 and 3 clinical trials for refractory or persistent early stage CTCL. 
Duvic et al. randomized 58 patients to two doses of bexarotene at 6.5mg/m2 per day and 650mg/m2 per day 
which was later modified to 300mg/m2 per day for at least 16 weeks or until progression. Responses of greater 
than 50% improvement in skin lesions were noted in 20% of patients at 6.5mg/m2 and 54% of patients had a 
response at 300mg/m2 and 67% of patients at doses greater than 300mg/m2. Seventy-three percent of patients 
that crossed over from 6.5mg/m2 to higher doses responded with the increased dose. Hypertriglyceridemia, 
hyperlipidemia, headache, and hypothyroidism were noted in a significant number of patients and were 
reversible with discontinuation of drug. Since increased toxicity was noted at dose level greater than 300mg/m2, 
recommended dose is 300mg/m2 in patients with refractory CTCL (4). 
 
Bexarotene has been developed as a gel and has been evaluated in clinical trials in patients with early stage 
CTCL. Based on the positive results of these studies, topical bexarotene is currently an FDA approved drug for 
the treatment of CTCL. In phase I and II trials conducted by Breneman and colleagues, topical bexarotene was 
applied to the skin lesions directly at different concentration levels of 0.1%, 0.5%, and 1% bexarotene gel. 
Patients started at the lowest concentration and applied the gel to affected skin lesions daily and titrated to twice 
daily dosing after 2 weeks and were tolerating the medication. As patients were able to tolerate gel application, 
bexarotene concentration was increased to 0.5% and then 1% and applying gel up to 4 times daily if tolerated. 
Most patients were able to tolerate 1% gel at twice daily dosing. The total dosage each patient received depended 
on the size and the number of lesions. Bexarotene gel was well tolerated and the most frequent adverse events 
in 67 patients were rash (73%), pruritus (33%), and pain (24%) with most being mild to moderate in severity. 
Systemic concentrations of bexarotene were extremely low and systemic side effects noted with oral bexarotene 
such as hyperlipidemia, hypothyroidism, and hypertriglyceridemia were not detected when medication was 
applied topically(5). Bexarotene 1% gel was also evaluated in a PhaseI/II trial for alopecia areata and was 
applied to half of participants’ scalp to assess response. Out of 42 patients, 31 (73%) experienced some dermal 
irritation with only 4 patients experiencing grade 3 dermal irritation.  Most common adverse event noted was 
mild erythema in the area of treatment that resolved with discontinuation of the drug (6). 
 
2.3 
Rationale 
 
In preclinical mouse models that develop ER-negative breast cancers, bexarotene showed significant activity in 
delaying mammary tumor development. In p53-null mice, bexarotene was given at 10mg/kg and 100mg/kg by 
gastric gavage and a 75% reduction in mammary tumor development was found in virgin mice at the higher 
dose level (7). In mouse mammary tumor virus (MMTV)-ErbB2 transgenic mice, focal tumors develop at eight 
months. Similar to humans, (MMTV)-ErbB2 mice undergo a multistage process of mammary tumorigenesis 
that progresses from normal mammary tissue to hyperplasia, mammary intraepithelial neoplasia (MIN) and 
finally invasive cancer. Li and colleagues gave bexarotene at 100mg/kg by oral gavage for 2 to 4 months in 
MMTV-erbB2 transgenic mice starting at three months of age. They found that bexarotene prevented the 
development of premalignant mammary lesions such as hyperplasia and MIN that is similar to human ductal 
carcinoma in situ (8). 
 
Based on these preclinical findings, oral bexarotene at 200mg/m2 has been evaluated in women at high risk for 
breast cancer based on their genetic risk. Bexarotene was found to reduce cyclin D1 RNA expression in breast 
cells from postmenopausal women (9). A nonsignificant reduction in Ki-67 expression was also seen in these 
post-menopausal women. Significant systemic side effects such as hypertriglyceridemia, hypercholesterolemia, 
and hypothyroidism were also found and were reversible after discontinuation of the drug(9). These results 
demonstrated that bexarotene has a biological effect on breast cells in women at high risk of breast cancer.  

DCP Protocol Number MDA2016-08-02 
Protocol Version 14, Dated 4/27/2021 
 
DCP Protocol Template Version 8.5 
–9– 
08/31/2016 
 
 
In addition to repressing cyclin D1 in breast cancer cells, bexarotene has shown effects on cyclin D1 in lung 
cancer cell lines. Dragnev et al. showed that the combination of bexarotene 1-4µmol/L plus erlotinib 1-4µmol/L 
significantly decreased cyclin D1 expression in cyclin-E- and KRAS/p53-driven transgenic lung cancer cell 
lines. The combination of bexarotene 400mg/m2 per day plus erlotinib 150mg daily was evaluated in early stage 
non-small cell lung cancer patients in a window of opportunity trial and significant decreases in cyclin D1 were 
noted as well as an induction of necrosis and inflammatory responses (10).  
 
Topical Therapies in Chemoprevention 
Uptake has been low in chemoprevention medications such as tamoxifen and raloxifene due to its systemic side 
effects of menopausal symptoms and blood clots. Topical creams applied directly to the breast could affect the 
breast tissue without leading to systemic side effects. Mauvais-Jarvis and colleagues evaluated trans-4-
hydroxytamoxifen (4-OHT), an active metabolite of tamoxifen, by topical administration to the breast. They 
evaluated 4-OHT absorption through the skin and its metabolism. Topical 4-OHT was applied directly over the 
breast in patients with invasive breast cancer and subsequently underwent mastectomy for their tumor. 
Concentration of 4-OHT was evaluated in breast tissue cytosol as well as nuclear extract and plasma samples 
taken at the time of surgery. 4-OHT was detected in the cytosol as well as in the nuclear extract as early as 24 
hours of application and decreased in concentration over time at 7 days after application. Plasma concentrations 
of 4-OHT was low but 4-OHT metabolites were present in the plasma but not detected in the breast tissue. This 
showed that topical application bypassed the first pass hepatic metabolism of the drug. Mauvais- Jarvis et al. 
also evaluated the topical application of 4-OHT on the breast versus the abdomen and found retention of the 
drug in the breast and delayed plasma concentrations of 4-OHT when compared to application on the abdomen 
(11). 
 
Rouanet et al. evaluated 4-OHT in a pre-surgical trial of 55 postmenopausal women with invasive ER positive 
breast cancer. Patients applied 4-OHT for 2 to 3 weeks at various dose levels compared to another group 
receiving oral tamoxifen at 20mg/day. They found that tissue proliferation decreased as measured by Ki-67 
levels between baseline and after treatment. There was a significant decrease in proliferation in the topical 
treatment arms with lower plasma concentrations of tamoxifen compared to oral treatment (12). Lee and 
colleagues evaluated 4-OHT in women with DCIS for 6 to 10 weeks prior to surgery. Women were randomized 
to either 4-OHT (4mg/day) or oral tamoxifen (20mg/day) and assessed change in Ki-67 in their DCIS lesions. 
Tissue concentration of drug was similar between 4-OHT and oral tamoxifen whereas systemic concentrations 
of 4-OHT were lower than oral tamoxifen. Changes in proliferation were also similar across both arms. No 
serious adverse events were noted with 4-OHT in this study. Bexarotene is similar to retinoids and thus more 
likely to have skin reactions than 4-OHT (13). 
 
We hypothesize that topical bexarotene can be applied to the breasts as a chemoprevention agent with 
penetration to the breast tissue and without having high systemic levels of drug and subsequent side effects and 
toxicity as seen with oral bexarotene. Data from chemoprevention studies with topical tamoxifen support the 
concept of topical agents penetrating into the breast tissue and exhibiting biological activity in the tissue. 
Preclinical models have clearly shown the effect of bexarotene in reducing the incidence of estrogen receptor 
negative breast cancer. Based on this data, we propose a phase I study to evaluate topical bexarotene in women 
at elevated risk for developing breast cancer. 
 
Rationale for including Alcohol and Tobacco Assessment Questionnaires 
Increasing evidence suggests that tobacco and alcohol use are risk factors in the development of intraepithelial 
neoplasia and cancer. In addition, tobacco and alcohol use may adversely affect agent intervention, for example 
by altering the safety profile or metabolism of a drug. Standardized assessments of tobacco and alcohol use 
during clinical trials will aid in understanding the potential relationship between the use of these products and 
clinical endpoints or cancer prevention biomarkers. Therefore, NCI, DCP is including assessment of tobacco 
and alcohol use at baseline and (include follow-up timepoint), to determine the potential impact of tobacco and 

DCP Protocol Number MDA2016-08-02 
Protocol Version 14, Dated 4/27/2021 
 
DCP Protocol Template Version 8.5 
–10– 
08/31/2016 
 
alcohol use on 1) treatment toxicity and symptom burden, and 2) the efficacy of treatment intervention. 
 
 
3. 
SUMMARY OF STUDY PLAN 
 
A. Dose Escalation Group 
We will recruit women at high risk for breast cancer to this phase I study. We will use topical bexarotene 1% 
gel and this will be applied to one unaffected breast for 4 weeks. Participants will be assigned to one of three 
different dose levels. Bexarotene gel volume is estimated to be 1ml for 1g of gel which contains 10mg of 
bexarotene. Therefore, the three dose cohorts will be 10mg (1ml) every other day, 10mg (1ml) daily, 20mg 
(2ml) daily. Dose Limiting Toxicity (DLT) is defined as a grade 2 skin adverse event that persists for at least 6 
days or any grade 3 or greater adverse event possibly, probably, or definitely related to the study drug.  In 
addition, a DLT will be a grade 2 skin adverse event that recurs and persists for at least 3 days.  A conservative 
modification of the standard “3+3” design will be applied. The first three participants will be assigned to the 
lowest dose level. New cohorts of 3-4 participants will not be treated until toxicity has been evaluated for all 
current participants for 4 weeks.  Group assignment algorithm is explained in Section 13.4 and dose escalation 
is illustrated in Figure 1.  The Maximum Tolerated Dose (MTD) will be defined as the highest dose level with 
at most 2 participants with DLT in 10 participants treated.  
 
Figure 1: Dose Escalation Schema for Bexarotene 1% gel 
 
 
 
 
Bexarotene gel will be provided by Valeant pharmaceuticals and repackaged by DCP pharmacy in dose metered 
pumps for dispensing the correct dose for application. Participants will begin application of the gel to the upper 
outer and upper inner quadrants of one breast every other day for one week and then increase to daily for 3 
weeks if they are assigned to daily dosing arm. If participants are assigned to every other day dosing, they will 
continue in this manner for the entire 4 weeks. Participants that are assigned to 20 mg (2ml) daily will first start 
with application of 10mg (1ml) to the breast every other day for 1 week, then increase to 10mg (1ml) daily for 
1 week, and then increase to 20mg (2ml) daily for the remaining 2 weeks as long as it is tolerated. Participants 
can also participate in an optional core breast biopsy of the upper outer or inner quadrant at the end of study 
treatment and receive compensation for additional expenses associated with the biopsy, such as additional travel 
expenses, time missed from work or other expenses associated with the biopsy visit. All participants will need 

DCP Protocol Number MDA2016-08-02 
Protocol Version 14, Dated 4/27/2021 
 
DCP Protocol Template Version 8.5 
–11– 
08/31/2016 
 
to come in for clinic visits for toxicity assessment and blood collection. All participants will receive a follow-
up phone call from the site investigator or designee 30 days ± 7 days after completion of study drug to assess 
for any further AE and document resolution of any acquired AE during treatment. 
 
As of Oct 2019, enrollment was completed to the first dose cohort and the second dose cohort was stopped early 
due to DLTs. No DLTs were experienced in the first dose cohort of 10 patients that applied 10mg of bexarotene 
to the breast every other day. In the second dose cohort, participants applied 10mg daily after tolerating 
application of every other day for one week. Four participants were enrolled in this cohort and 1 participant 
withdrew early due to adverse events unrelated to study drug. Two DLTs were noted in the remaining patients 
and thus enrollment was stopped at the second dose level. Therefore, no patients will be enrolled to the third 
dose level due to concerns for toxicity. MTD is 10mg/breast/every other day. 
 
B. Dose Expansion Group 
A dose expansion group of additional 10 participants will be enrolled and treated at the MTD to further evaluate 
safety and drug penetration into the breast tissue. There will be a ramp up to the desired dose similar to the 
ramp up schedule in the dose escalation group. At any time in the dose expansion cohort, if there are ≥30% 
DLT among participants, the trial will be terminated. Assessment for dose limiting toxicities will occur 
continuously as participants are enrolled into the dose expansion group. This will be determined after the third 
and each successive participant until 10 participants are in the group. Participants in this group will receive 
treatment for 4 weeks and undergo the same schedule of events as the dose escalation group. All participants in 
the dose expansion cohort will have a core breast biopsy at end of treatment and receive compensation for 
additional expenses associated with the biopsy, such as additional travel expenses, time missed from work or 
other expenses associated with the biopsy visit. All participants will receive a follow-up phone call from the 
site investigator or designee 30 days ± 7 days after completion of study drug to assess for any further AE and 
document resolution of any acquired AE during treatment. 
 
 
4. 
PARTICIPANT SELECTION 
 
4.1 
Inclusion Criteria 
4.1.1 
Participants must be at high risk as defined by a history of breast cancer (invasive or DCIS) and be at 
least 5 years out from diagnosis, or lobular carcinoma in situ (LCIS), or proliferative benign breast 
disease such atypical ductal hyperplasia (ADH), atypical lobular hyperplasia(ALH) or genetic test 
confirmation of BRCA 1/2 mutation carrier or have a breast cancer risk assessment >1.7% in 5 years 
or a lifetime risk >20%.  
 
4.1.2 
No evidence of disease (in situ or invasive cancer that would normally be treated by resection) at trial 
entry as determined by the investigator. Diagnosis of invasive cancer must be at least 5 years prior to 
initiation on trial. 
 
4.1.3 
Female ≥18 years as breast cancer is extremely rare in women less than 18 years. 
 
4.1.4 
ECOG performance status ≤1 (Karnofsky ≥70%; see Appendix A) 
 
4.1.5 
Participants must have normal organ and marrow function as defined below: 
 
 
Leukocytes 
≥3,000/microliter 
 
 
Absolute neutrophil count ≥1,500/microliter 
 
 
Platelets 
≥100,000/microliter 
 
 
Total bilirubin 
within normal institutional limits 
 
 
AST (SGOT)/ALT (SGPT) ≤1.5 × institutional upper limit of normal (ULN) 
 
 
Creatinine 
≤ 1.5x institutional ULN 

DCP Protocol Number MDA2016-08-02 
Protocol Version 14, Dated 4/27/2021 
 
DCP Protocol Template Version 8.5 
–12– 
08/31/2016 
 
 
 
Hemoglobin  
 
≥10 g/dL 
 
 
TSH 
 
 
within normal institutional limits 
 
 
Triglycerides 
 
≤300 mg/dl 
 
 
Total Cholesterol 
≤300 mg/dl 
 
4.1.6 
≥ 6 months from all previous breast cancer treatment (including endocrine therapy). 
 
4.1.7 
Participants must have adequate accessible breast tissue as determined by the treating physician, 
consisting of one breast unaffected by invasive cancer, which has not been radiated. A history of benign 
core biopsy of this breast will be permitted. 
 
4.1.8 
Participants need to have had any breast imaging with a normal/benign (bi-rads 1 or 2) result within 
180 days of Day 0 and no further routine breast imaging planned during the course of the study (4 
weeks). Exception: if the mammogram result was a bi-rads 0 and the imaging work-up (ultrasound 
and/or MRI) result comes back normal/benign (bi-rads 1 or 2) before treatment initiation, then 
participant is eligible. 
 
4.1.9 
For women of childbearing potential; negative pregnancy testing within 72 hours prior to or on study 
visit #1 (Day 0) and willingness to use adequate contraception during the study intervention. OR Post-
menopausal defined as any one of the following 1) prior hysterectomy, 2) absence of menstrual period 
for 1 year in the absence of prior chemotherapy or 3) absence of menstrual period for 2 years in women 
with a prior history of chemotherapy exposure who were pre-menopausal prior to chemotherapy. In 
women of childbearing potential, effective contraception must be used for one month prior to the 
initiation of therapy, during therapy, and for at least one month following discontinuation of therapy. 
It is recommended that two reliable forms of contraception be used simultaneously. If participants are 
interested in enrolling and have not met the requirement for contraception, they will be seen in the clinic 
in 1 month for re-evaluation once they have met this requirement and ensure all other eligibility criteria 
is met prior to dose assignment. 
 
4.1.10 Willingness to comply with all study interventions and follow-up procedures including the ability to 
apply the study drug to the breast. 
 
4.1.11 Ability to understand and the willingness to sign a written informed consent document. 
 
 
4.1.12 Ability to avoid exposure of the treated breast area to sunlight and artificial ultraviolet light during the 
use of bexarotene gel. 
 
 
4.2 
Exclusion Criteria 
 
4.2.1 
History of allergic reactions attributed to compounds of similar chemical or biologic composition to 
bexarotene gel, oral or topical retinoids. 
 
4.2.2 
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic 
congestive heart failure, unstable angina pectoris, cardiac arrhythmia, thromboembolic disease, or 
psychiatric illness/social situations that would limit compliance with study requirements. 
 
 
4.2.3 
Pregnant, or had given birth, or nursed at any time during the last 12 months. 
 
4.2.4 
Women with a history of any cancer within the last 3 years, except for non-melanoma skin cancer. See 
4.1.1 as history of breast cancer must be at least >5 years from diagnosis. 

DCP Protocol Number MDA2016-08-02 
Protocol Version 14, Dated 4/27/2021 
 
DCP Protocol Template Version 8.5 
–13– 
08/31/2016 
 
 
4.2.5 
Prior bilateral breast surgery (mastectomy, segmental mastectomy, or breast augmentation surgery 
including breast implants or breast reductions) or combination of breast radiation and surgery involving 
both breasts. 
 
4.2.6 
Prior history or evidence of metastatic breast cancer 
 
4.2.7 
Prior history of histologically confirmed bilateral invasive breast cancer. 
 
4.2.8 
Current use or <6 months since use of SERMS or Aromatase inhibitors or any other investigational 
treatment for breast cancer prevention or therapy.  
 
4.2.9 
Skin lesions that disrupt the stratum corneum (eg. eczema, ulceration) or any breakdown of the skin. 
 
4.2.10  Current use of a retinol containing agent or any retinoid analogue drug within the last 30 days. 
 
4.2.11 Dietary Vitamin A intake ≥5,000 IU/day (as determined by dietary supplementation) 
 
4.2.12 Treatment with any investigational drug or investigational biologic within 30 days of initiating study 
treatment or during the study. 
 
4.2.13 History of HIV or active hepatitis C. 
 
 
4.3 
Inclusion of Women and Minorities 
 
Women of all races and ethnic groups are eligible for this trial.   
 
 
4.4 
Recruitment and Retention Plan 
 
Participants will be recruited for enrollment on this trial from the cancer prevention center, with particular 
attention to enhancing racial, ethnic and socioeconomic diversity. Prior to enrollment, the study will be 
discussed in detail with the participant, and possible toxicities will be presented. The informed consent 
document will be reviewed with the participant by the study physician or other medical staff authorized by the 
participating institution to obtain Informed Consent. Please refer to the study-specific Recruitment and 
Retention Plan for more details.  
 
 
5. 
AGENT ADMINISTRATION 
 
Intervention will be administered on an outpatient basis. Reported AEs and potential risks are described in 
Section 6.2.  
 
 
5.1 
Dose Regimen and Dose Groups/Gel Application 
 
Participants will self-administer the bexarotene gel.  Gel will be applied to one unaffected breast after freshly 
washed, either by washcloth, shower, or bath, preferably in the morning, (in order to minimize potential transfer 
to the partner at night). If morning shower is not possible, the subject will wash the one unaffected breast with 
a washcloth before gel application, to remove the prior day’s dose. If a morning swim is planned, application 

DCP Protocol Number MDA2016-08-02 
Protocol Version 14, Dated 4/27/2021 
 
DCP Protocol Template Version 8.5 
–14– 
08/31/2016 
 
should be after the swim. No washing or immersion in water should occur for at least 4 hours following gel 
application. The gel should not be used near fire, flame or while smoking since it is flammable due to alcohol. 
Once dry, the gel is no longer flammable. Detailed instructions regarding application are in Appendix B and a 
demonstration of gel application will occur during the Baseline/Dose Assignment visit. The treated breast 
should be covered at all times to avoid transfer to other people and protect from natural or artificial sunlight; 
contact is permitted after the treated area has been washed with soap and water and washing is allowable after 
a minimum of 4 hours post-application. 
 
Each bexarotene gel canister will contain 33 mL gel product and will be metered to dispense 10 mg of 1% 
bexarotene gel per pump.  Cohorts 1 and 2 will receive 1 bexarotene gel canister containing 30 reliable doses. 
Cohort 3 will receive 2 bexarotene gel canisters containing 30 reliable doses each for a total of 60 reliable doses. 
The expansion cohort will receive either 1 or 2 bexarotene gel canisters depending on the maximum tolerated 
dose (MTD) as determined during the dose escalation group phase to assess bexarotene concentration in the 
breast tissue. 
 
 
5.2 
Gel Administration/Run-in Procedures  
 
Each Bexarotene gel canister will contain 30 reliable doses of product metered to dispense 1mL per actuation, 
1g of bexarotene gel per actuation. One gram of bexarotene gel contains 10mg of active bexarotene.  
 
Participants in all dose levels will be instructed to apply the gel at 10mg (1 mL) every other day to one 
unaffected breast for the first 7 days of treatment. After the Day 8 phone call and confirmation that toxicity is 
at an acceptable range, participants assigned to 10mg/breast/daily will increase applications to daily. 
Participants assigned to 10mg/breast/every other day will continue to apply gel every other day. Participants 
assigned to 20mg/breast/daily will increase from 10mg (1mL) every other day to daily application for another 
7 days. After the Day 15 visit and confirmation of acceptable toxicity, participants will increase to 20mg (2 
mL) to the one unaffected breast daily for the remaining 2 weeks.  All participants will continue to apply the 
gel to one unaffected breast as directed for a duration of 4 weeks. Participants in the dose expansion group will 
apply the gel with the same ramp up schedule as those in the dose escalation group for that dose level. 
 
Participants will also receive moisturizing lotion [CeraVe] that can be applied to the breast to reduce and prevent 
redness that can be related from the study drug. CeraVe will be provided to all participants and they will be 
instructed to apply to the treated breast in the evening or at least 4 hours after application of study drug so it 
will not interfere with the absorption of study drug.  
 
 
5.3 
Contraindications 
 
Participants are to avoid exposure of the treated breast skin to natural or artificial sunlight. This includes 
sunbathing or the use of tanning beds with the breasts exposed. Also, women who have dermatologic conditions 
causing the breakdown of skin should not use bexarotene gel.  
 
 
5.4 
Concomitant Medications 
 
Women who are receiving endocrine therapy for breast cancer treatment or chemoprevention including 
tamoxifen, letrozole, anastrozole, fulvestrant, or exemestane at the time of screening will not be eligible. 
Participants may not have a history of allergic reactions attributed to compounds of similar chemical or biologic 
composition to bexarotene or retinoids. Participants must limit vitamin A intake to <5,000 IU/day. Participants 
should not concurrently use products that contain DEET (N,N-diethyl-m-toluamide), a common component of 

DCP Protocol Number MDA2016-08-02 
Protocol Version 14, Dated 4/27/2021 
 
DCP Protocol Template Version 8.5 
–15– 
08/31/2016 
 
insect repellant products. Otherwise, there are no restrictions on other medications, herbs, and vitamin and 
mineral supplements (other than study agents) while participating in the study.  
 
All medications (prescription and over-the-counter), vitamin and mineral supplements, and/or herbs taken by 
the participant will be documented on the concomitant medication CRF and will include: 1) start and stop date, 
dose and route of administration, and indication. Medications taken for a procedure (e.g., biopsy) should also 
be included. 
 
 
5.5 
Dose Modification 
 
For any grade 1 adverse events or grade 2 adverse events that are not hypertriglyceridemia or skin related, no 
dose modifications will be made. For any grade 2 skin toxicity possibly, probably, or definitely related to study 
drug that persists for 3 days, drug will be held for 3 days. Participants at the lowest dose level will restart gel 
application at every 3 days dosing for 3 days (1 dose) and then increase back to every other day dosing. If grade 
2 skin toxicity recurs and persists for 3 days, drug application will be discontinued and will be classified as a 
DLT. Participants in the second dose level (10mg daily) will hold for 3 days if toxicity is noted and resume at 
10mg every other day for 4 days (2 doses) and then increase back to daily dosing. Participants at the highest 
dose level (20mg daily) will hold for 3 days and resume at 10mg daily for 3 days (3 doses) and then increase 
back to 20mg daily. Participants experiencing Grade 3 or Grade 4 toxicities of any attribution will be taken off 
study drug. Please see Table 1 for dose modification algorithm. 
 
Table 1: Dose Modification Algorithm for Grade 2 Skin Adverse Events related to Bexarotene Gel 
 
Dose Level 
If Grade 2 Skin AE 
Persists for 3 Days 
Dose Modification 
(If Skin AE resolves to 
≤ Grade 1) 
If Grade 2 Skin  AE  
Recurs and Persists for 
3 Days 
10mg/breast/every 
other day 
Hold Study Drug 
for 3 days 
Restart drug application 
at 
10mg/breast/every 
three days for 3 days (1 
dose) and then increase 
to original dose 
Stop Drug 
10mg/breast/daily 
Hold Study Drug 
for 3 days 
Restart drug application 
at 
10mg/breast/every 
other day for 4 days ( 2 
doses) and then increase 
to original dose 
Stop Drug 
20mg/breast/daily 
Hold Study Drug 
for 3 days 
Restart 
drug 
at 
10mg/breast/ daily for 3 
days (3 doses) and then 
increase to original dose 
Stop Drug 
 
Hypertriglyceridemia is a known systemic side effect with oral bexarotene formulation and will be monitored 
throughout the study. If grade 1 hypertriglyceridemia is noted, lipid profile will be continued to monitor weekly 
and at Day 22 blood specimen will be added for monitoring.  If grade 2 hypertriglyceridemia is noted, drug will 
be held for 1 week and triglycerides will be rechecked. If normal, drug application will be resumed at the 1 dose 
level below. If triglycerides continue to be elevated or increase again, drug will be discontinued. If grade 3 
hypertriglyceridemia is noted, drug will be discontinued and participant will be initiated on a statin. 
Triglycerides will be checked weekly until resolution and if elevation persists after 30 days, participant will be 
referred to their primary care physician for further management. 

DCP Protocol Number MDA2016-08-02 
Protocol Version 14, Dated 4/27/2021 
 
DCP Protocol Template Version 8.5 
–16– 
08/31/2016 
 
 
 
5.6 
Adherence/Compliance 
 
5.6.1 
Participants will be considered compliant if they took 75% of their bexarotene gel dose. 
 
5.6.2 
The following methods will be used to monitor each participant’s agent compliance: 
1) Participants will be given a Gel Diary and instructed to initial it each time a dose is taken. 
2) Canisters will be weighed when released and also upon return. 
 
 
6. 
PHARMACEUTICAL INFORMATION 
 
6.1 
Bexarotene (IND #, NCI, Division of Cancer Prevention)   
 
Targretin® (bexarotene) 1% gel contains bexarotene and is intended for topical application. Bexarotene is a 
member of a subclass of retinoids that selectively activate retinoid X receptors (RXRs). These retinoid receptors 
have biologic activity distinct from that of retinoic acid receptors (RARs). The chemical name is 4-[1-(5,6,7,8-
tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)ethenyl] benzoic acid, and the structural formula is as 
follows: 
 
Bexarotene is an off-white to white powder with a molecular weight of 348.48 and a molecular formula of 
C24H28O2. It is insoluble in water and slightly soluble in vegetable oils and ethanol, USP. Bexarotene gel is a 
clear gelled solution containing 1.0% (w/w) bexarotene in a base of dehydrated alcohol, USP, polyethylene 
glycol 400, NF, hydroxypropyl cellulose, NF, and butylated hydroxytoluene, NF. 
 
Plasma concentrations of bexarotene were determined during clinical studies in patients with CTCL or 
following repeated single or multiple-daily dose applications of bexarotene gel 1% for up to 132 weeks. Plasma 
bexarotene concentrations were generally less than 5 ng/mL and did not exceed 55 ng/mL. However, only two 
patients with very intense dosing regimens (> 40% BSA lesions and QID dosing) were sampled. Plasma 
bexarotene concentrations and the frequency of detecting quantifiable plasma bexarotene concentrations 
increased with increasing percent body surface area treated and increasing quantity of bexarotene gel applied. 
The sporadically-observed and generally low plasma bexarotene concentrations indicated that, in patients 
receiving doses of low to moderate intensity, there is a low potential for significant plasma concentrations 
following repeated application of bexarotene gel.  Bexarotene is highly bound (>99%) to plasma proteins.  The 
plasma proteins to which bexarotene binds have not been elucidated, and the ability of bexarotene to displace 
drugs bound to plasma proteins and the ability of drugs to displace bexarotene binding have not been studied.  
The uptake of bexarotene by organs or tissues has not been evaluated. 
 
 
Four bexarotene metabolites have been identified in plasma following oral administration of bexarotene: 6- and 
7-hydroxy-bexarotene and 6- and 7-oxo-bexarotene.  In vitro studies suggest that cytochrome P450 3A4 is the 
major cytochrome P450 responsible for formation of the oxidative metabolites and that the oxidative 
metabolites may be glucuronidated.  The oxidative metabolites are active in in vitro assays of retinoid receptor 

DCP Protocol Number MDA2016-08-02 
Protocol Version 14, Dated 4/27/2021 
 
DCP Protocol Template Version 8.5 
–17– 
08/31/2016 
 
activation, but the relative contribution of the parent and any metabolites to the efficacy and safety of bexarotene 
gel is unknown. 
 
The renal elimination of bexarotene and its metabolites was examined in patients with Type 2 diabetes mellitus 
following oral administration of bexarotene.  Neither bexarotene nor its metabolites were excreted in urine in 
appreciable amounts. 
 
 
6.2 
Reported Adverse Events and Potential Risks 
 
The safety of bexarotene gel has been assessed in clinical studies of 117 patients with CTCL who received 
bexarotene gel for up to 172 weeks.  In the multicenter open label study, 50 patients with CTCL received 
bexarotene gel for up to 98 weeks.  Patients in the CTCL trials were instructed to apply a generous layer of the 
gel to the CTCL lesion starting at every other day dosing and and gradually applied more frequently up to two 
or four times a day.  This area was variable by patient but resulted in a larger volume compared to this phase I 
trial in which is the application is limited to 1ml of bexarotene gel to only one breast which is approximately 
1% of the body surface area. The mean duration of therapy for these 50 patients was 199 days.  The most 
common adverse events reported with an incidence at the application site of at least 10% in patients with CTCL 
were rash, pruritus, skin disorder, and pain. Adverse events leading to dose reduction or study drug 
discontinuation in at least two patients were rash, contact dermatitis, and pruritus. 
Of the 49 patients (98%) who experienced any adverse event, most experienced events categorized as mild (9 
patients, 18%) or moderate (27 patients, 54%).  There were 12 patients (24%) who experienced at least one 
moderately severe adverse event.  The most common moderately severe events were rash (7 patients, 14%) and 
pruritus (3 patients, 6%).  Only one patient (2%) experienced a severe adverse event (rash). In the patients with 
CTCL receiving bexarotene gel, adverse events reported regardless of relationship to study drug at an incidence 
of ≥5% are presented in Table 2 (5). 
 
 
Table 2. Incidence of All Adverse Events* and Application Site Adverse Events with Incidence ≥5% for 
All Application Frequencies of Bexarotene Gel in the Multicenter CTCL Study 
 
Body System/Preferred Term 
All Adverse Events 
Application Site Adverse Events 
 
N = 50 
n (%) 
N = 50 
n (%) 
Skin and Appendages 
          Contact Dermatitis1 
7 (14) 
4 (8) 
          Exfoliative Dermatitis 
3 (6) 
0 
          Pruritus2 
18 (36) 
9 (18) 
          Rash3 
36 (72) 
28 (56) 
          Maculopapular Rash 
3 (6) 
0 
          Skin Disorder (NOS)4  
13 (26) 
9 (18) 
          Sweating 
3 (6) 
0 
Body as a Whole 
          Asthenia 
3 (6) 
0 
          Headache 
7 (14) 
0 
          Infection 
9 (18) 
0 
          Pain 
15 (30) 
9 (18) 
Cardiovascular 
          Edema 
5 (10) 
0 
          Peripheral Edema 
3 (6) 
0 

DCP Protocol Number MDA2016-08-02 
Protocol Version 14, Dated 4/27/2021 
 
DCP Protocol Template Version 8.5 
–18– 
08/31/2016 
 
Hemic and Lymphatic 
          Leukopenia 
3 (6) 
0 
          Lymphadenopathy 
3 (6) 
0 
          WBC Abnormal 
3 (6) 
0 
Metabolic and Nutritional 
          Hyperlipemia 
5 (10) 
0 
Nervous 
          Paresthesia 
3 (6) 
3 (6) 
Respiratory 
          Cough Increased 
3 (6) 
0 
          Pharyngitis 
3 (6) 
0 
 
* Regardless of association with treatment 
Includes Investigator terms such as: 
1 Contact dermatitis, irritant contact dermatitis, irritant dermatitis 
2 Pruritus, itching, itching of lesion 
3 Erythema, scaling, irritation, redness, rash, dermatitis 
4 Skin inflammation, excoriation, sticky or tacky sensation of skin; NOS = Not Otherwise Specified 
 
Bexarotene 1% gel was also evaluated in a PhaseI/II trial for alopecia areata and was applied to half of 
participants’ scalp to assess response. Out of 42 patients, 31 (73%) experienced some dermal irritation with 
only 4 patients experiencing grade 3 dermal irritation.  Most common adverse event noted was mild erythema 
in the area of treatment that resolved with discontinuation of the drug (6). 
 
 
6.3  
Availability 
 
Bexarotene 1% gel will be supplied by Valeant Pharmaceuticals and will be repackaged in metered dose pumps 
by the Division of Cancer Prevention (DCP), NCI.  
 
Each bexarotene gel canister will contain 30 reliable doses of product metered to dispense 1mL per actuation, 
1g of bexarotene gel per actuation. One gram of bexarotene gel contains 10mg of active bexarotene.  
 
Cohorts 1 and 2 will receive 1 bexarotene gel canister containing 30 reliable doses. Cohort 3 will receive 2 
bexarotene gel canisters containing 30 reliable doses each for a total of 60 reliable doses.  
 
The expansion cohort will receive either 1 or 2 bexarotene gel canisters depending on the maximum tolerated 
dose (MTD) as determined during the dose escalation group phase to assess bexarotene concentration in the 
breast tissue. 
 
 
6.4 
Agent Distribution 
 
Agents will only be released by NCI, DCP after documentation of IRB approval of the DCP-approved protocol 
and consent is provided to DCP and the collection of all Essential Documents is complete (see DCP website for 
description of Essential Documents).  
 
NCI, DCP-supplied agents may be requested by the Investigator (or their authorized designees) at each 
Organization. DCP guidelines require that the agent be shipped directly to the institution or site where the agent 
will be prepared and administered. DCP does not permit the transfer of agents between institutions (unless prior 

DCP Protocol Number MDA2016-08-02 
Protocol Version 14, Dated 4/27/2021 
 
DCP Protocol Template Version 8.5 
–19– 
08/31/2016 
 
approval from DCP is obtained). DCP does not automatically ship agents; the site must make a request. Agents 
are requested by completing the DCP Clinical Drug Request form (NIH-986) (to include complete shipping 
contact information) and faxing or mailing the form to the DCP agent repository contractor: 
 
John Cookinham 
MRIGlobal 
DCP Repository 
1222 Ozark Street 
North Kansas City, MO 64116 
Phone: (816) 360-3805 
FAX: (816) 753-5359 
Emergency Telephone: (816) 360-3800 
 
6.5  
Agent Accountability 
 
The Investigator, or a responsible party designated by the Investigator, must maintain a careful record of the 
inventory and disposition of all agents received from DCP using the NCI Drug Accountability Record Form 
(DARF) or an institutionally-approved accountability system. The Investigator is required to maintain adequate 
records of receipt, dispensing and final disposition of study agent. This responsibility may be delegated to the 
site coordinator, institutional pharmacist or their designees.  Include on receipt record from whom the agent 
was received and to whom study agent was shipped, date, quantity and batch or lot number. On dispensing 
record, note quantities and dates study agent was dispensed to and returned by each participant. Dr. Thomas or 
her representatives will be responsible for study agent accountability for participants at UT MD Anderson 
Cancer Center. DCP requirements for agent accountability and the required forms are available on the DCP 
website. 
 
6.6 
Packaging and Labeling 
 
Bexarotene gel is packaged by NCI, DCP Repository.  
 
Bexarotene gel is packaged in a container-closure system which consists of a pouch in a canister, a 1 mL 
pump, and a protective cap that covers the pump. A single actuation delivers 1mL of gel at 1g/mL. Each 
canister will have a label printed with the concentration and weight of gel, expiration date, protocol number 
and “Bexarotene 1% Gel” along with the statement “Caution: New Drug- Limited by Federal law (US) to 
investigational use”. Each canister is packaged in a carton with the sample label. Detailed instruction for gel 
application will be provided.”  The canister will also have a bright label “DO NOT DISCARD- PLEASE 
RETURN TO CLINIC”. 
 
6.7 
Storage 
 
All study drug must be stored in a secure limited-access area. Store at 25°C (77°F) with excursions permitted 
to 15°-30°C (59°-86°F) in accordance with labeled storage requirements. Avoidance of humidity and protecting 
from light is not necessary and packaging will provide this protection. Investigational labeling will include 
instructions to keep the product out of the reach of children. 
 
 
 
6.8 
Registration 
 
Screening and Registration into the DMI Database:  

DCP Protocol Number MDA2016-08-02 
Protocol Version 14, Dated 4/27/2021 
 
DCP Protocol Template Version 8.5 
–20– 
08/31/2016 
 
Once informed consent has been signed, participants will be registered into the DMI database.  The DMI 
database will assign a participant’s PID upon completion of the registration process. 
 
Screening/Registration into site-specific databases: 
The DMI is the database of record for the study. Registration should occur per the procedures outlined above. 
If the site staff needs to enter study data into site-specific electronic databases per institutional requirements, 
they should do so in accordance with their institutional policies and procedures. 
 
Appropriate CRFs must be completed for any participant who signs an informed consent. If a consented 
participant is a screen failure and deemed ineligible, the following CRFs must be completed: 1) the Registration 
CRF; 2) the Inclusion and Exclusion CRFs showing why the participant is ineligible, 5) the Off-Study CRF, 4) 
the Adverse Event CRF, 5) the Concomitant Medication CRF and 6) the Verification CRF. If no Adverse Event 
and/or Concomitant Medications were assessed by the time the participant is deemed ineligible, the “NONE” 
box will be checked to complete both CRFs.  All participants who sign an informed consent must formally go 
off study. All participant registration information will be entered into DMI. If a participant experiences a serious 
Adverse Event during the screening process, a Serious Adverse Event (SAE) form must be completed. 
 
 
6.9 
Blinding and Unblinding Methods 
 
This is not a blinded study. Participants and the PI’s team will not be blinded to the dose of bexarotene gel.  
 
 
6.10 
Agent Destruction/Disposal 
 
At the completion of investigation, all undispensed study agent will be returned to NCI, DCP Repository 
according to the DCP “Guidelines for AGENT RETURNS” and using the DCP form “Return Drug List”.  The 
Guidelines and form are available on the DCP website. Unused drug, that has been dispensed to participants, 
but that is returned unused by the participants, will be disposed of by the site staff following institutional 
guidelines after canisters have been weighed and the weights have been recorded. 
 
 

DCP Protocol Number MDA2016-08-02 
Protocol Version 14, Dated 4/27/2021 
 
DCP Protocol Template Version 8.5 
–21– 
08/31/2016 
 
7. 
CLINICAL EVALUATIONS AND PROCEDURES 
 
7.1 
Schedule of Events 
 
Evaluation/ 
Test 
Baseline 
Testing/Prestudy 
Evaluation/ 
Registration (Within 
30 days prior to or on 
Day 0) 
Day 0 
Day 1 Day 
8 
±2 days 
 
Phone 
Call 
Day 15 
±2 days 
Day 28 
±2 days 
 
Follow 
Up Call 
 
30 days ± 
7 
days 
after Day 
28 
Informed Consent 
X 
 
 
 
 
 
 
Registration 
X 
 
 
 
 
 
 
Medical History 
X 
 
 
 
 
X 
 
Confirm Eligibility 
 
X 
 
 
 
 
 
Dose assignment 
 
X 
 
 
 
 
 
Baseline Symptom 
Assessment 
X 
 
 
 
 
 
 
Concomitant Medications 
X 
 
 
 
 
X 
X 
Vitals 
X 
 
 
 
X 
X 
 
Physical Exam 
X 
 
 
 
 
 
 
Breast Exam 
X 
 
 
 
X 
X 
 
Breast Cup Size 
X 
 
 
 
 
 
 
Weight/ Height/ Last 
Menstrual Perioda 
X 
 
 
 
 
X 
 
Routine Laboratory Testsb 
X 
 
 
 
X 
X 
 
Pregnancy Testc 
X 
X 
 
 
 
X 
 
Research Blood Sampled  
 
X 
 
 
 
X 
 
Breast Imaginge 
X 
 
 
 
 
 
 
Dispense Study Agentf 
 
X 
 
 
 
 
 
Start Study Medication 
 
 
X 
 
 
 
 
Adverse Events/ Symptom 
Assessment 
 
 
 
X 
X 
X 
X 
Dermatology Evaluationg 
 
 
 
 
X 
X 
 
Review Gel Diary 
 
X 
 
X 
X 
X 
 
Collect Study Agent 
 
 
 
 
 
X 
 
Core Biopsyh 
 
 
 
 
 
X 
 
Tobacco and Alcohol Use 
Assessment 
Xi 
 
 
 
 
Xj 
 
Telephone Contact 
 
 
 
X 
 
 
X 
 
a) Do not repeat height measurement and last menstrual period data collection after Baseline Testing. 
b) Routine laboratory tests include: CBC (hemoglobin, hematocrit, RBC, WBC, platelet count) with differential 
(neutrophils, lymphocytes, monocytes, eosinophils, basophils) and CMP (Na+, K+, Cl-, CO2 (bicarbonate), BUN, 
creatinine, glucose), liver function tests (ALT, AST, total bilirubin, Alk Phos, Albumin), triglyerides, total 
cholesterol, high density lipoprotein (HDL), low density lipoprotein (LDL), thyroid stimulating hormone (TSH), 
free T3 and free T4, and calcium. 
c) In women of child bearing potential a pregnancy test (urine or serum) must be done within 30 days prior to D0. 
Within 72 hours prior to or on Day 0 the pregnancy test (urine or serum) will be repeated and results must be 
known before starting study drug. If a urine pregnancy test is performed, the test must be done in the clinic or in 
the lab. Repeat pregnancy test will be done at the end of study as well.  
• 
If pregnancy test result is positive at Baseline (any time before Day 0), the participant is a Screen Failure. 

DCP Protocol Number MDA2016-08-02 
Protocol Version 14, Dated 4/27/2021 
 
DCP Protocol Template Version 8.5 
–22– 
08/31/2016 
 
• 
If pregnancy test result is positive on Day 0, do not dispense the study agent, take participant off-study, 
complete the Off-Study Case Report Form (CRF), follow the pregnancy to term and complete the Outcome 
of Pregnancy Case Report Form (CRF).  
• 
If a pregnancy is discovered after Day 0, instruct the participant to stop applying the gel, take participant off-
study, complete the Off-Study CRF, follow the pregnancy to term and complete the Outcome of Pregnancy 
CRF. 
d) Research blood sample for serum bexarotene level.  
e) Participants need to have had any breast imaging with a normal/benign (bi-rads 1 or 2) result within 180 days of 
Day 0 and no further routine breast imaging planned during the course of the study (4 weeks). Exception: if the 
mammogram result was a bi-rads 0 and the imaging work-up (ultrasound and/or MRI) result comes back 
normal/benign (bi-rads 1 or 2) before treatment initiation, then participant is eligible. 
f) 
Participants must be instructed to apply the last dose of their study medication on the last day of the study (Day 
28).   
g) Dermatology evaluation within 72 hours of study visit if participant experiences a grade 3 skin event or continues 
to have a persistent grade 2 skin event despite dose modification.  
h) The core biopsy at Day 28 is optional for dose escalation cohort participants. The biopsy is mandatory for 
participants in the dose expansion cohort at Day 28. If the participant is on aspirin, non-steroidal anti-
inflammatory drugs or Vitamin E, she will be instructed to discontinue these 7 days prior to the end of treatment 
biopsy.  
i) 
See Appendix D “Alcohol and Tobacco Use Assessment Questionnaires – Baseline”. 
j) 
See Appendix E “Alcohol and Tobacco Use Assessment Questionnaires – Follow Up”. 
 
 
7.2 
Baseline Testing/Prestudy Evaluation 
 
Days -30 to 0: Baseline Testing/Prestudy Evaluation/ Registration 
The following procedures will be conducted during Baseline Testing or within 30 days prior to Day 0: 
• 
Informed consent must be obtained prior to starting any further study procedures. 
• 
Registration: Once informed consent has been signed, participants will be registered into the DMI 
database. The DMI database will assign a participant’s ID upon completion of the registration process. 
Participants will also be registered into site-specific registry databases as applicable. 
• 
Medical history, to include a review of breast cancer history (if applicable) and previous medical 
history, previous surgeries, reproductive history, family history, demographic information, including 
age and race. 
• 
Use of concomitant medications will be reviewed. 
• 
Baseline symptom assessment.  
• 
A physical examination to include vital signs (blood pressure, heart rate, respiratory rate) and breast 
exam. Breast cup size will be documented. 
• 
Height, weight to calculate body mass index (BMI).  The day of the last menstrual period will be 
recorded. 
• 
Pre-study routine laboratory evaluations will include the following: 
- 
HEMATOLOGY: CBC (hemoglobin, hematocrit, RBC, WBC, platelet count) with 
differential (neutrophils, lymphocytes, monocytes, eosinophils, basophils 
- 
CHEMISTRY: Na+, K+, Cl-, CO2, BUN, creatinine, glucose 
- 
Liver Function: ALT, AST, Tbili, Alk Phos, Albumin 
- 
Lipid profile, thyroid function tests, and calcium 
• 
In women of child bearing potential, a pregnancy test (urine or serum) must be done within 30 days 
prior to D0. Within 72 hours prior to or on Day 0 the pregnancy test (urine or serum) will be repeated 

DCP Protocol Number MDA2016-08-02 
Protocol Version 14, Dated 4/27/2021 
 
DCP Protocol Template Version 8.5 
–23– 
08/31/2016 
 
and results must be known before starting study drug. If a urine pregnancy test is performed, the test 
must be done in the clinic or in the lab. 
- 
If pregnancy test result is positive at Baseline (any time before Day 0), the participant is a 
Screen Failure. 
- 
If pregnancy test result is positive on Day 0, do not dispense drug, take participant off-
study, complete the Off-Study Case Report Form (CRF), follow the pregnancy to term and 
complete the Outcome of Pregnancy Case Report Form (CRF). 
- 
If a pregnancy is discovered after Day 0, instruct the participant to stop taking drug, take 
participant off-study, complete the Off-Study CRF, follow the pregnancy to term and 
complete the Outcome of Pregnancy CRF. 
• 
Participants need to have had any breast imaging with a normal/benign (bi-rads 1 or 2) result within 
180 days of Day 0 and no further routine breast imaging planned during the course of the study (4 
weeks). Exception: if the mammogram result was a bi-rads 0 and the imaging work-up (ultrasound 
and/or MRI) result comes back normal/benign (bi-rads 1 or 2) before treatment initiation, then 
participant is eligible. 
• 
Tobacco and Alcohol Use Assessment, using the Baseline questionnaires. See Appendix D “Alcohol 
and Tobacco Use Assessment Questionnaires – Baseline”. Refer to Appendix F for resources for 
alcohol and tobacco quitting. These resources can be given to individuals if there is concern about 
alcohol or tobacco dependence. It is not expected that investigators will refer individuals for assistance 
or that they will undertake the care of individuals for alcohol or tobacco dependence. 
• 
Confirm eligibility: At the completion of the screening period, eligibility must be confirmed. Only after 
eligibility is confirmed, eligible participants can be assigned to a dose level and scheduled for the on 
study tests and procedures. 
Day 0 
The following procedures will be conducted on Day 0: 
• 
For women of childbearing potential a pregnancy test must be completed within 72 hours prior to or on 
Day 0. Either a serum or urine pregnancy test may be performed. If a urine pregnancy test is performed, 
the test must be done in the clinic or in the lab: 
- 
If pregnancy test result is positive on Day 0, do not dispense drug, take participant off-
study, complete the Off-Study Case Report Form (CRF), follow the pregnancy to term and 
complete the Outcome of Pregnancy Case Report Form (CRF). 
- 
If a pregnancy is discovered after Day 0, instruct the participant to stop taking drug, take 
participant off-study, complete the Off-Study CRF, follow the pregnancy to term and 
complete the Outcome of Pregnancy CRF. 
- 
Study drug should be initiated on the second or third day of a normal menstrual period. 
• 
Research Blood Sample for serum bexarotene concentration.  
• 
 
• 
Depending on the dose assignment, participants will receive: 
o Bexarotene 1 % gel 10mg/breast/every other day x 4 weeks 
o Bexarotene 1% gel  10mg/breast/daily x 4 weeks 
o Bexarotene 1% gel  20mg/breast/daily x 4 weeks 
• 
Review guidelines for gel application with the participant. 
• 
Review Gel Diary with the participant (see Appendix C). Provide instructions on use of diary. 

DCP Protocol Number MDA2016-08-02 
Protocol Version 14, Dated 4/27/2021 
 
DCP Protocol Template Version 8.5 
–24– 
08/31/2016 
 
All data will be captured on the appropriate eCRFs. 
 
 
7.3 
Evaluation During Study Intervention 
 
Day 1 
• 
Participants will initiate study agent on Day 1. 
Day 8 ±2 days: Phone Call 
• 
Participants will receive a phone call from the PI or designee for an assessment of adverse events.  To 
assess skin toxicity please ask the participant non-leading questions such as “Have you noted any 
changes in the skin of your breast?”  If the participant reports yes, then utilize the plain language guide 
(Appendix G) to ask more probing questions as needed. Refer to Table 3 for modified CTCAE for 
assessing skin toxicity of bexarotene gel applied to the breast skin.  
• 
Gel diary will be reviewed.  
 
Day 15 ±2 days 
• 
Participants will return for an assessment of adverse events and breast exam.  To assess skin toxicity 
please ask the participant non-leading questions such as “Have you noted any changes in the skin of 
your breast?”  If the participant reports yes, then utilize the plain language guide (Appendix G) to ask 
more probing questions as needed. Refer to Table 3 for modified CTCAE for assessing skin toxicity of 
bexarotene gel applied to the breast skin. Gel diary will be reviewed. Vital signs will be measured. 
Routine blood sample will be obtained during the visit to evaluate for systemic toxicity.  
• 
All skin AEs will be photographed by medical photography services.  
• 
If Grade 3 adverse event is noted on exam, drug will be held and participant will be evaluated by 
dermatology within 72 hours of the study visit. 
 
7.4 
Evaluation at Completion of Study Intervention 
Day 28 ±2 days 
• 
Participants will return for an assessment of adverse events and breast exam. To assess skin toxicity 
please ask the participant non-leading questions such as “Have you noted any changes in the skin of 
your breast?”  If the participant reports yes, then utilize the plain language guide (Appendix G) to ask 
more probing questions as needed. Refer to Table 3 for modified CTCAE for assessing skin toxicity of 
bexarotene gel applied to the breast skin.   Medical history and concomitant medications will be 
reviewed. Gel diary will be reviewed and collected. Routine and research blood samples will be 
obtained during the visit. Pregnancy test will be repeated at this visit. The breast core biopsy will be 
scheduled at this visit for those participants in the dose escalation cohort who opt for the procedure and 
for all participants in the dose expansion cohort.  Breast tissue will be evaluated for bexarotene 
concentration. Remaining study drug will be collected at this visit. 
• 
Vital signs will be measured.  Weight will be recorded.  
• 
All skin AEs will be photographed by medical photography services. 
• 
If Grade 3 adverse event is noted on exam, participant will be evaluated by dermatology within 72 
hours of the study visit. 

DCP Protocol Number MDA2016-08-02 
Protocol Version 14, Dated 4/27/2021 
 
DCP Protocol Template Version 8.5 
–25– 
08/31/2016 
 
• 
Tobacco and Alcohol use assessment will be performed on Day 28, using the “Alcohol and Tobacco 
Use Assessment Questionnaires – Follow Up” questionnaires (see Appendix E). 
 
7.5 
Post-intervention Follow-up Period 
 
All participants will receive a follow-up phone call from the site investigator or designee 30 days ± 7 days after 
Day 28 study visit to assess for any further AE and document resolution of any acquired AE during treatment. 
If the AE has not resolved, then the participant will be scheduled for a follow up visit with their primary care 
provider for ongoing management of this AE.  The use of concomitant medications will be recorded.   
 
 
7.6 
Methods for Clinical Procedures 
 
Breast core biopsy (see also section 10):  
 
The breast core biopsy (image guided) will not be performed prior to drug initiation in the dose escalation 
cohort, and is optional at Day 28.  The breast core biopsy (image guided) is required of participants in the dose 
expansion group at Day 28. A 14-gauge needle will be used. Every effort will be made to collect 4 cores of 
tissue, with the minimum of 3 cores per participant. Refer to Section 10 for details of specimen management.  
 
 
 
 
8. 
CRITERIA FOR EVALUATION AND ENDPOINT DEFINITION 
 
8.1 
Primary Endpoint: Toxicity and Safety 
 
The primary objective of this study is to determine the safety and toxicity of topical 1% bexarotene gel 
application to the breasts of healthy women at high risk for breast cancer for duration of 4 weeks. Women with 
ADH, ALH, LCIS, breast cancer survivors (DCIS or invasive) ≥ 5 years from their diagnosis, BRCA 1/2 
mutation carriers, and women with elevated risk for breast cancer ≥1.7% in 5 years or lifetime risk ≥20% will 
be recruited. Three dose levels are considered (10mg every other day, 10mg daily, and 20mg daily). Dose 
Limiting Toxicity (DLT) is defined as a grade 2 skin adverse event that persists for at least 6 days or any grade 
3 or greater adverse event possibly, probably, or definitely related to the study drug. In addition, a DLT will be 
a grade 2 skin adverse event that recurs and persists for at least 3 days.  A conservative modification of the 
standard “3+3” design will be applied. The first cohort of 3 participants will be treated at the first dose level 
(10mg every other day). New cohorts of participants will not be treated until toxicity has been fully evaluated 
for all current participants for 4 weeks. We will add another 4 participants when only 1 or less participants 
experience DLT in 6 treated participants.  We will only escalate dose to the next higher level when 20% or less 
of total participants experience a DLT. At any dose level, the algorithm is as follows: 
 
(1) If 0 or 1 out of 3 participants experience DLTs (≤1/3), an additional cohort of 3 participants will be 
treated at the same dose level. If total number of participants experiencing DLT at that dose level is 1 
or less out of 6 (≤ 1/6), we will enroll another 4 at the same dose level.  
(2) If at any time 2 or more participants experience DLTs in 3 or 6 (≥ 2/3 or ≥ 2/6) or 3 or more experience 
DLT in 10 participants (≥3/10), then the dose escalation will stop, and the next lower dose will be 
considered as the maximum tolerated dose (MTD).  
(3) In 10 participants at each dose level, if we observe 2 or less DLTs, a cohort of 3 will be treated at the 
next higher level.  If 3 or more in 10 participants experience DLT, we will stop accrual to that level and 
above, and claim the regimen as to be too toxic for that level or above. 

DCP Protocol Number MDA2016-08-02 
Protocol Version 14, Dated 4/27/2021 
 
DCP Protocol Template Version 8.5 
–26– 
08/31/2016 
 
 
 
MTD is defined the highest dose level with at most 2 participants with DLTs in 10 participants treated.  
 
Once MTD is identified, we will enroll another 10 participants into MTD and these participants will have 
mandatory biopsies before and after 4 weeks of treatment.  We will continuously monitor aggregate DLTs in 
these participants together with the 10 participants treated during the dose escalation part of the study.  If at any 
time the posterior probability of observing a DLT rate of at least 20% exceeds 70%, i.e., Pr(DLT rate >=0.20 | 
Data) >70%, given the prior of the DLT rate of beta (0.2, 0.8), we will stop the trial and claim the dose is too 
toxic.    Given the above rule, the boundaries for early stopping due to excessive DLT are Total Number of 
Participants with DLTs/Total Number of Participants >= 4/11~14, 5/15~19, and 6/20.   Combining with the 
boundaries during dose escalation phase, i.e., stop accrual at the dose level if Total Number of Participants with 
DLTs/Total Number of Participants >= 2/3, 2/6, 3/10, 4/11~14, 5/15~19, and 6/20, the early stopping 
probability for this level will be 15%, 51%, 82% if the true DLT rate is 0.10, 0.20, and 0.30, respectively. 
 
Given that there are 3 dose levels and 10 participants enrolled at each level, and 10 additional participants at 
MTD, it is anticipated that 40 participants will be enrolled and treated and up to 40 will be evaluable at the end 
of this study. 
 
Skin Toxicity 
CTCAE criteria will be utilized to grade adverse events. Skin adverse events are expected to be the most 
common in this study. Bexarotene is similar to retinoids and retinoid dermatitis is very common and can be 
managed with temporarily withholding drug and restarting at a decreased frequency until tolerated by the 
individual. Dose modifications for each dose level have been defined in Section 5.5 to guide management of  
participant experiences of an adverse event  
 
CTCAE criteria for skin will be modified (Table 3) for this study as adverse events are expected to be localized 
to the breast area. This modified criteria was also utilized by Talpur et al. when they evaluated bexarotene 1% 
gel on the scalp of participants with alopecia areata (6). Please see Table 3 for modified CTCAE criteria.  Use 
plain language when talking to the participant about skin AEs.   Refer to Appendix G for a plain language guide 
to support both phone and in-person assessments of skin application AEs. 
 
Participants will be shown how much area of their breast is considered 25% of the treated area so they can 
clearly describe their symptoms and the extent of the affected area. They will also be instructed to draw around 
reddened areas so they can clearly see if an area is expanding or improving and relay that information to the 
study team. 
 
Table 3: Modified CTCAE for assessing skin toxicity of bexarotene gel applied to the breast skin.  These 
assessments will be made on the breast skin (application site). 
 
 
Grade 1 
Grade 2 
Grade 3 
Grade 4 
Dry Skin 
No 
erythema 
or 
pruritus 
With erythema or 
pruritus 
With erythema and 
pruritus 
- 
Pain of Skin 
Mild pain 
Moderate Pain 
Severe Pain 
- 
Photosensitivity 
Painless erythema 
Mild to Moderate 
Pain with erythema 
Erythema 
with 
blistering or skin 
breakdown 
Erythema with 
ulceration 
Pruritus 
Mild, 
requiring 
topical intervention 
Intense, 
with 
changes 
from 
Intense, 
constant, 
limiting ADL or 
- 

DCP Protocol Number MDA2016-08-02 
Protocol Version 14, Dated 4/27/2021 
 
DCP Protocol Template Version 8.5 
–27– 
08/31/2016 
 
scratching, 
oral 
intervention needed 
sleep, oral steroids 
needed 
Rash, maculopapular 
Macules or papules 
<25% 
of 
treated 
area, with or without 
symptoms (pruritus, 
burning, tightness) 
Macules or papules 
>25% 
of 
treated 
area, 
with 
or 
without symptoms 
(pruritus, burning, 
tightness), limiting 
instrumental ADL 
Macules or papules 
>25% of the treated 
area, 
with 
or 
without symptoms 
(pruritus, burning, 
tightness), limiting 
self care ADL 
- 
Urticaria 
Asymptomatic 
or 
mild symptoms, not 
requiring therapy 
Moderate, 
limited 
local 
therapy 
needed, 
limiting 
instrumental ADL 
Urticarial 
lesions 
covering >30% of 
application 
site; 
oral 
or 
IV 
intervention 
indicated 
- 
 
 
8.2 
Secondary Endpoints 
 
8.2.1 
Markers of Systemic Toxicity: Based on data from oral bexarotene in women at high risk for breast 
cancer, bexarotene alters lipid levels, thyroid function, and calcium levels. Therefore, serum biomarkers to be 
tested will be Total Cholesterol, triglycerides, LDL, HDL, TSH, free T4, free T3, and calcium. Evaluation and 
changes in these biomarkers will be done at baseline, 15, and Day 28 visits. 
 
8.2.2 
Bexarotene Concentration: Bexarotene concentration will be determined using LC-MS/MS (5500 or 
similar; AB SCIEX, Foster City, CA) according to methods developed and qualified at IIT Research Institute 
(IITRI) for the study.  
 
 
8.2.3 
Effect of Bexarotene on Tissue Markers:  
 
i. 
One of the four cores collected from the core biopsies from post treatment (all dose expansion cohort 
participants and optional for dose escalation group) will be formalin-fixed and paraffin embedded 
(FFPE) for future histological analysis. These cores will be stored for future use.   
ii. 
One of the four cores collected from the core biopsies post treatment will be placed in RNALater and 
utilized for future biomarker analysis such as gene expression of RNA biomarkers.  
 
 
8.3 
Off-Agent Criteria  
 
Participants may stop taking study agent for the following reasons: completed the protocol-prescribed 
intervention, AE or SAE including a DLT, inadequate agent supply, noncompliance, concomitant medications, 
medical contraindication, or became pregnant. Participants experiencing Grade 3 or Grade 4 toxicities of any 
attribution will be taken off study drug. Participants will continue to be followed, if possible, for safety reasons 
and in order to collect endpoint data according to the schedule of events. Participants that receive agent but 
withdraw without initiating treatment will be replaced and will not be followed or evaluable for DLTs. 
 
 
8.4 
Off-Study Criteria 
 

DCP Protocol Number MDA2016-08-02 
Protocol Version 14, Dated 4/27/2021 
 
DCP Protocol Template Version 8.5 
–28– 
08/31/2016 
 
Participants may go ‘off-study’ for the following reasons: the protocol intervention and any protocol-required 
follow-up period is completed, AE/SAE, lost to follow-up, non-compliance, concomitant medication, medical 
contraindication, withdraw consent, death, determination of ineligibility (including screen failure),and 
pregnancy. 
 
 
8.5 
Study Termination 
 
NCI, DCP as the study sponsor has the right to discontinue the study at any time.  
 
 
9. 
CORRELATIVE/SPECIAL STUDIES 
 
9.1 
Rationale for Methodology Selection 
 
Section 8 outlines our primary and secondary endpoint biomarkers. The primary endpoint measurement will be 
done by assessing toxicity and adverse events using modified CTCAE criteria and standard clinical methods. 
CTCAE criteria for skin will be modified (Table 3) for this study as adverse events are expected to be localized 
to the breast area. This modified criteria was also utilized by Talpur et al. when they evaluated bexarotene 1% 
gel on the scalp of patients with alopecia areata (6). For secondary endpoints, again, we choose methods that 
have been previously published, either by our group or other investigators, that are widely available, practical, 
and financially preferable.  
 
 
9.2 
Comparable Methods 
 
The methodologies described above are those previously used (see details above), and the resulting data will be 
able to be compared to existing data. 
 
 
10. 
SPECIMEN MANAGEMENT  
 
10.1 
Laboratories 
 
10.1.1 Bexarotene concentration analysis in the serum and breast tissue will be performed in Dr. Miguel 
Muzzio’s laboratory at IITRI. 
 
10.1.2 Thyroid function tests, lipid profile, calcium, and all standard labs will be performed at UT MD 
Anderson Outpatient Laboratory as MD Anderson is the only site participating in the study. 
 
 
 
10.2 
Collection and Handling Procedures 
 
 
Blood collection:  
Peripheral blood will be obtained by venipuncture at baseline, Day 15, and at Day 28 visits. Blood will be 
collected for bexarotene concentration and other biomarkers mentioned in section 8.2.1 and 8.2.2. Fasting for 
the blood draws for lipid analysis is recommended but is not mandated. 
 
For the purpose of tracking samples: All cryovials will be labeled to identify all sample vials.  Blood specimen 
for bexarotene level will be collected in 4mL Li- Heparin tubes such as BD 367884 Plasma Tube, 60 USP Units 

DCP Protocol Number MDA2016-08-02 
Protocol Version 14, Dated 4/27/2021 
 
DCP Protocol Template Version 8.5 
–29– 
08/31/2016 
 
of Lithium Heparin (spray-coated) or similar. Specimen will be centrifuged at 1000G for 15 min at -4degrees 
Celsius. Plasma will be separated and aliquoted to 0.5-1.0 ml/tube in at least 2 vials. Plasma specimens will be 
stored in a secure -80 degree Celsius freezer (range -70 °C to -80 °C) 
 
Breast Core Biopsy (see also section 7.6):  
The breast core biopsy (image guided) will not be performed prior to treatment initiation in the dose escalation 
cohort and is optional at Day 28.  The breast core biopsy (image guided) is required of participants in the dose 
expansion group at Day 28. A 14-gauge needle will be used. Every effort will be made to collect 4 cores of 
tissue, with the minimum of 3 cores per participant at each time point.  
 
Planned usage of core biopsies is shown in Table 4.   
 
Core biopsy specimens #1 and 2 will be fresh frozen in liquid nitrogen for bexarotene concentration using LC-
MS/MS (5500 or similar; AB SCIEX, Foster City, CA). 
 
Core biopsy specimens #3 will be fixed in formalin and embedded in a single paraffin block.  One H&E slide 
will be prepared for adequacy and histological assessment. Tissue will be considered adequate for research 
assays if the H&E stained slide from the block demonstrates at least one terminal duct lobular unit (TDLU) in 
the tissue core.  Usually each terminal duct lobular unit contains 200 to 2500 cells. If no terminal duct lobular 
units are seen, deeper sections from the tissue block will be obtained.    
 
Core biopsy specimens #4 will be placed immediately into RNAlater.  Each biopsy sample will be placed in 
(1) prefilled cryovial and then stored in a secure 4 degree Celsius refrigerator (range of 4-6 °C) for a 
minimum of 24 hours and up to 7 days. The cryovials wi l l t h en b e remo v ed from the refrigerator and 
placed in a secure -80 degree Celsius freezer (range -70 °C to -80 °C).  Core #2 will be used for exploratory 
gene expression analysis. 
 
 
Table 4. Planned use of core tissue biopsies: 
Core 
Preparation 
Analyses 
1-2 
Fresh frozen 
Bexarotene concentration using LC-MS/MS 
(5500 or similar; AB SCIEX, Foster City, CA) 
3 
Formalin fixed, paraffin-embedded 
Used to make 5 slides and then used for 
histological evaluation at to rule out cancer and 
stored for future use.  
 
4 
RNAlater at 4C then transferred to    
-80°C (range -70°C to -80°C) 
freezer 
Exploratory gene expression analysis 
 
 
10.3 
Shipping Instructions 
 
All samples will be shipped in compliance with the International Air Transport Association (IATA) Dangerous 
Goods Regulations. 
 
At the completion of the study, all plasma specimens and tissue specimens for bexarotene concentration will be 
shipped to Miguel Muzzio at IITRI for analysis. Samples will be sent to: 
 
Miguel Muzzio 
Analytical Chemistry Division 

DCP Protocol Number MDA2016-08-02 
Protocol Version 14, Dated 4/27/2021 
 
DCP Protocol Template Version 8.5 
–30– 
08/31/2016 
 
IIT Research Institute 
10 West 35th Street, 8E9-1  
Chicago, IL 60616 
Tel: 312.567.4909 
Fax: 312.567.4466 
Email:MMuzzio@iitri.org 
 
 
10.4 
Tissue Banking 
 
Biologic specimens collected during the conduct of each clinical trial that are not used during the course of the 
study will be considered deliverables under the contract and thus the property of the NCI. At study completion, 
NCI reserves the option to either retain or relinquish ownership of the unused biologic specimens. If NCI retains 
ownership of specimens, the Contractor shall collect, verify and transfer the requested biologic specimens from 
the site to a NCI-specified repository or laboratory at NCI’s expense.  
 
 
 
11. 
REPORTING ADVERSE EVENTS  
 
DEFINITION: AE means any untoward medical occurrence associated with the use of a drug in humans, 
whether or not considered drug related. An AE can therefore be any unfavorable and unintended sign), 
symptom, or disease temporally associated with participation in a study, whether or not related to that 
participation. This includes all deaths that occur while a participant is on a study. 
 
Please note that all abnormal clinical laboratory values that are determined to be of clinical significance based 
on a physician’s assessment are to be reported as AEs. Those labs determined to be of no clinical significance 
or of unknown clinical significance (per the physician’s assessment) should not be reported as AEs. Any lab 
value of unknown clinical significance should continue to be investigated/followed-up further for a final 
determination, if possible. 
 
A list of AEs that have occurred or might occur  can be found in §6.2 Reported Adverse Events and Potential 
Risks, as well as the Investigator Brochure or package insert.  
 
 
11.1 
Adverse Events 
 
11.1.1 Reportable AEs 
 
All AEs that occur after the informed consent is signed and baseline assessments are completed (including run-
in) must be recorded on the AE CRF (paper and/or electronic) whether or not related to study agent. 
 
11.1.2 AE Data Elements: 
 
The following data elements are required for AE reporting. 
• 
AE verbatim term (Include at application site, if applicable) 
• 
NCI Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0) AE term (MedDRA 
lowest level term) 
• 
CTCAE (MedDRA) System Organ Class (SOC) 
• 
Event onset date and event ended date 

DCP Protocol Number MDA2016-08-02 
Protocol Version 14, Dated 4/27/2021 
 
DCP Protocol Template Version 8.5 
–31– 
08/31/2016 
 
• 
Treatment assignment code (TAC) at time of AE onset 
• 
Severity grade 
• 
Attribution to study agent (relatedness) 
• 
Whether or not the event was reported as a SAE 
• 
Whether or not the subject dropped due to the event 
• 
Outcome of the event 
 
11.1.3  Severity of AEs 
 
 
 
11.1.3.1 
Identify the AE using the CTCAE version 4.0. The CTCAE provides descriptive terminology 
(MedDRA lowest level term) and a grading scale for each AE listed. A copy of the CTCAE can be found at 
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm 
 
AEs will be assessed according to the grade associated with the CTCAE term. AEs that do not have a 
corresponding CTCAE term will be assessed according to the general guidelines for grading used in the CTCAE 
v4.0. as stated below.  
 
 
CTCAE v4.0 general severity guidelines:  
 
Grade 
Severity 
Description  
1 
Mild 
Mild; asymptomatic or mild symptoms; clinical or diagnostic 
observations only; intervention not indicated. 
2 
Moderate 
Moderate; minimal, local or noninvasive intervention indicated; 
limiting age-appropriate instrumental activities of daily living 
(ADL)*. 
3 
Severe 
Severe or medically significant but not immediately life-threatening; 
hospitalization or prolongation of hospitalization indicated; 
disabling; limiting self-care ADL**. 
4 
Life-threatening 
Life-threatening consequences; urgent intervention indicated. 
5 
Fatal 
Death related to AE. 
   
ADL 
*Instrumental ADL refers to preparing meals, shopping for groceries or clothes, using the telephone, managing 
money, etc. 
 
**Self-care ADL refers to bathing, dressing and undressing, feeding self, using the toilet, taking medications, 
and not bedridden. 
 
11.1.4 Assessment of relationship of AE to treatment 
 
 
The possibility that the AE is related to study agent will be classified as one of the following: not related, 
unlikely, possible, probable, definite. 
  
11.1.5 Follow-up of AEs 
 
All AEs, including lab abnormalities that in the opinion of the investigator are clinically significant, will be 
followed according to good medical practices and documented as such.  
 
 

DCP Protocol Number MDA2016-08-02 
Protocol Version 14, Dated 4/27/2021 
 
DCP Protocol Template Version 8.5 
–32– 
08/31/2016 
 
11.2 
Serious Adverse Events  
 
11.2.1 DEFINITION: Regulations at 21 CFR §312.32 (revised April 1, 2014) defines an SAE as any untoward 
medical occurrence that at any dose has one or more of the following outcomes: 
 
• 
Death 
• 
A life-threatening AE 
• 
Inpatient hospitalization or prolongation of existing hospitalization 
• 
A persistent or significant incapacity or substantial disruption of the ability to perform normal life 
functions 
• 
A congenital anomaly or birth defect 
• 
Important medical events that may not be immediately life-threatening or result in death or 
hospitalization should also be considered serious when, based upon appropriate medical 
judgment, they may jeopardize the participant and may require intervention to prevent one of 
the other outcomes. 
 
 
 
11.2.2 Reporting SAEs  
SAEs should be reported to the following 3 entities: 1) NCI DCP, 2) DCP’s regulatory contractor CCSA, and 
3) MDACC, the CLO.  Detailed reporting instructions are provided below.  In addition, the site will follow the 
IRB requirements for SAE reporting.   
 
11.2.2.1 
SAEs 
will 
be 
reported 
on 
the 
DCP 
SAE 
Report 
Form 
found 
at 
http://prevention.cancer.gov/clinical-trials/clinical-trials-management/protocol-information-office/pio-
instructions-and-tools/2012-consortia. 
 
11.2.2.2 
Contact the DCP Medical Monitor by phone within 24 hours of knowledge of the event.  
 
Marjorie Perloff, MD 
Division of Cancer Prevention 
National Cancer Institute 
9609 Medical, Rm 5E544 
Rockville, MD 200850 
Office Tel (240)276-7097 
Cell (240)731-1772 
Email: perloffm@mail.nih.gov 
 
Include the following information when calling the Medical Monitor: 
• 
Date and time of the SAE 
• 
Date and time of the SAE report 
• 
Name of reporter 
• 
Call back phone number 
• 
Affiliation/Institution conducting the study 
• 
DCP protocol number 
• 
Title of protocol 
• 
Description of the SAE, including attribution to drug 
 
 

DCP Protocol Number MDA2016-08-02 
Protocol Version 14, Dated 4/27/2021 
 
DCP Protocol Template Version 8.5 
–33– 
08/31/2016 
 
11.2.2.3 
Contact the Consortium Lead Organization (CLO) PI, Dr. Powel Brown, or designee by phone, 
fax or email listed on the protocol face page within 24 hours of knowledge of the event.  The same information 
reported to the DCP Medical Monitor should be provided to the CLO PI or designee via email, phone or fax 
within 24 hours of knowledge of the event. 
 
11.2.2.4 
Written SAE reports should be forwarded to DCP’s Regulatory Contractor CCS Associates, 
Inc. (CCSA; phone: 650-691-4400) at safety@ccsainc.com within 48 hours of learning of the event using the 
fillable PDF SAE Report Form.    
 
11.2.2.5 
The CLO PI, Dr. Brown, or designee must be copied on the email sent to DCP’s Regulatory 
Contractor CCS Associates, Inc. 
 
11.2.2.6 
Valeant Drug Safety (drugsafety@valeant.com) and Ali Hussain (Ali.Hussain@valeant.com) 
should be copied on the email sent to DCP’s Regulatory Contractor CCS Associates, Inc. 
 
11.2.2.7 
The DCP Medical Monitor and CCSA regulatory and safety staff will determine which SAEs 
require FDA submission as IND safety reports. 
 
11.2.2.8 
The Site will comply with applicable regulatory requirements related to reporting SAEs to the 
IRB/IEC.  
 
11.2.3 Follow-up of SAE 
 
Site staff should send follow-up reports as requested when additional information is available. Additional 
information should be entered on the DCP SAE Report Form in the appropriate format. Follow-up information 
should be sent to DCP as soon as available. SAEs related to the study agent will be followed until resolved.  
 
12. 
STUDY MONITORING 
 
12.1 
Data Management 
 
This study will report clinical data using the Data Management Initiative (DMI) web-based application managed 
by the Consortium Biostatistics and Data Management Core.  Data Management Initiative (DMI) infrastructure 
has been developed in the Division of Quantitative Sciences (DQS), MD Anderson Cancer Center.  This 
infrastructure supplies integrated database and software services for web-based data collection, randomized 
treatment assignment, reporting, query, data download, and data quality management.  The DMI will be the 
database of record for the protocol and subject to NCI and FDA audit.  All DMI users will be trained to use the 
DMI system and will comply with the instructions in the protocol-specific “DMI User Manual” as well as 
applicable regulatory requirements such as 21 CFR; Part 11.  Data management procedures for this protocol 
will adhere to the Data Management Plan (DMP) on file at the DCP for contract HHSN261201200034I. 
 
 
12.2 
Case Report Forms 
 
Participant data will be collected using protocol-specific case report forms (CRF) developed from the standard 
set of DCP Chemoprevention CRF Templates and utilizing NCI-approved Common Data Elements (CDEs). 
The study will utilize electronic CRF (e-CRF) only, which will be viewed as screens in the DMI application. 
Site staff will enter data into the e-CRF in DMI. CRF amendments will be submitted to the DCP Protocol 
Information Office for review and approval.  Approved changes will be programmed into the DMI database by 
the Consortium Biostatistics and Data Management Core. 
 

DCP Protocol Number MDA2016-08-02 
Protocol Version 14, Dated 4/27/2021 
 
DCP Protocol Template Version 8.5 
–34– 
08/31/2016 
 
 
12.3 
Source Documents 
 
Source documentation will include only those documents containing original forms of data, including clinic 
charts, shadow files, hospital charts, and physician notes.  Data recorded directly on the CRFs designated as 
source documents (i.e., no prior written or electronic record of data) will be considered source data.  All other 
data recorded on the CRFs will not be considered source documentation. 
 
 
12.4 
Data and Safety Monitoring Plan 
 
The Data and Safety Monitoring Plan for the MD Anderson Consortium is on file at the DCP.  This study will 
be monitored by the MDACC Data and Safety Monitoring Board (DSMB), the data and safety monitoring board 
of record for this study.   The DSMB reports to the President, or his designee, as the on-campus representative 
of The University of Texas Board of Regents. It oversees the data and patient safety issues for clinical trials 
that originate at MD Anderson; that are coordinated or analyzed by MD Anderson and are not being monitored 
by any other DSMB; or have been designated as requiring DSMB monitoring at the request of the IRB, the 
CRC, or institution. The primary objectives of the DSMB are to ensure that patients' rights pertaining to 
participation in a research study are protected, and that patients' interests are prioritized over the interests of the 
scientific investigation. Responsibilities include: 
(a) Review interim analyses of outcome data (prepared by the study statistician or other responsible 
person at the time points defined in the study) approved by the IRB and additional time points as 
determined by the DSMB, and to recommend, if necessary, whether the study needs to be changed 
or terminated based on these analyses; 
(b) Determine whether, and to whom, outcome results should be released prior to the reporting of study 
results; 
(c) Review interim toxicity data and efficacy of treatment; 
(d) Review major research modifications proposed by the investigator or appropriate study committee 
prior to implementation (e.g., termination, dropping an arm based on toxicity results from the study 
or results of other studies, increasing target sample size). 
Refer to the Data and Safety Monitoring Plan for the MD Anderson Consortium on file at the DCP for further 
details. 
 
 
12.5 
Sponsor or FDA Monitoring 
 
The NCI, DCP (or their designee), pharmaceutical collaborator (or their designee), or FDA may monitor/audit 
various aspects of the study. These monitors will be given access to facilities, databases, supplies and records 
to review and verify data pertinent to the study. 
 
 
12.6 
Record Retention 
 
Clinical records for all participants, including CRFs, all source documentation (containing evidence to study 
eligibility, history and physical findings, laboratory data, results of consultations, etc.), as well as IRB records 
and other regulatory documentation will be retained by the Investigator in a secure storage facility in compliance 
with Health Insurance Portability and Accountability Act (HIPAA), Office of Human Research Protections 
(OHRP), Food and Drug Administration (FDA) regulations and guidances, and NCI/DCP requirements, unless 
the standard at the site is more stringent. The records for all studies performed under an IND will be maintained, 
at a minimum, for two years after the approval of a New Drug Application (NDA). For NCI/DCP, records will 
be retained for at least three years after the completion of the research. NCI will be notified prior to the planned 

DCP Protocol Number MDA2016-08-02 
Protocol Version 14, Dated 4/27/2021 
 
DCP Protocol Template Version 8.5 
–35– 
08/31/2016 
 
destruction of any materials. The records should be accessible for inspection and copying by authorized persons 
of the Food and Drug Administration. If the study is done outside of the United States, applicable regulatory 
requirements for the specific country participating in the study also apply. 
 
 
12.7 
Cooperative Research and Development Agreement (CRADA)/Clinical Trials Agreement (CTA) 
 
The agent(s) supplied by DCP, NCI, used in this protocol, is/are provided to the NCI under a Collaborative 
Agreement (CRADA, CTA) between the Valeant Pharmaceuticals North America LLC (hereinafter referred to 
as Collaborator(s)) and the NCI Division of Cancer Prevention. Therefore, the following obligations/guidelines, 
in addition to the provisions in the “Intellectual Property Option to Collaborator@ contained within the terms 
of award, apply to the use of Agent(s) in this study: 
 
12.7.1 Agent(s) may not be used for any purpose outside the scope of this protocol, nor can Agent(s) be 
transferred or licensed to any party not participating in the clinical study. Collaborator(s) data for Agent(s) are 
confidential and proprietary to Collaborator(s) and shall be maintained as such by the investigators. The 
protocol documents for studies utilizing investigational agents contain confidential information and should not 
be shared or distributed without the permission of the NCI. If an individual participating on the study or 
participant’s family member requests a copy of this protocol, the individual should sign a confidentiality 
agreement. A suitable model agreement can be downloaded from the DCP website. 
 
12.7.2 For a clinical protocol where there is an Investigational Agent used in combination with (an) other 
investigational Agent(s), each the subject of different collaborative agreements, the access to and use of data 
by each Collaborator shall be as follows (data pertaining to such combination use shall hereinafter be referred 
to as "Multi-party Data”). 
 
12.7.3 NCI must provide all Collaborators with prior written notice regarding the existence and nature of any 
agreements governing their collaboration with NIH, the design of the proposed combination protocol, and the 
existence of any obligations that would tend to restrict NCI's participation in the proposed combination protocol. 
 
12.7.4 Each Collaborator shall agree to permit use of the Multi-Party Data from the clinical trial by any other 
Collaborator solely to the extent necessary to allow said other Collaborator to develop, obtain regulatory 
approval, or commercialize its own investigational agent. 
 
12.7.5 Any Collaborator having the right to use the Multi-Party Data from these trials must agree in writing 
prior to the commencement of the trials that it will use the Multi-Party Data solely for development, regulatory 
approval, and commercialization of its own investigational agent. 
 
12.7.6 Clinical Trial Data and Results and Raw Data developed under a collaborative agreement will be made 
available exclusively to Collaborator(s), the NCI, and the FDA, as appropriate. All data made available will 
comply with HIPAA regulations. 
 
12.7.7 When a Collaborator wishes to initiate a data request, the request should first be sent to the NCI, who 
will then notify the appropriate investigators of Collaborator's wish to contact them. 
 
12.7.8 Any manuscripts reporting the results of this clinical trial must be provided to DCP for immediate 
delivery to Collaborator(s) for advisory review and comment prior to submission for publication. 
Collaborator(s) will have 30 days (or as specified in the CTA) from the date of receipt for review. Collaborator 
shall have the right to request that publication be delayed for up to an additional 30 days in order to ensure that 
Collaborator’s confidential and proprietary data, in addition to Collaborator(s)’s intellectual property rights, are 
protected. Copies of abstracts must be provided to DCP for forwarding to Collaborator(s) for courtesy review 

DCP Protocol Number MDA2016-08-02 
Protocol Version 14, Dated 4/27/2021 
 
DCP Protocol Template Version 8.5 
–36– 
08/31/2016 
 
as soon as possible and preferably at least three days prior to submission, but in any case, prior to presentation 
at the meeting or publication in the proceedings. Press releases and other media presentations must also be 
forwarded to DCP prior to release. Copies of any manuscript, abstract, and/or press release/ media presentation 
should be sent to the Protocol Information Office at NCI_DCP_PIO@mail.nih.gov.  
 
 
 
 
The Protocol Information Office will forward manuscripts to the DCP Project Officer for distribution to the 
Collaborator(s). No publication, manuscript or other form of public disclosure shall contain any of 
Collaborator’s confidential/proprietary information. 
 
 
 
13. 
STATISTICAL CONSIDERATIONS 
 
13.1 
Study Design/Description 
 
This is a phase I study to evaluate the safety and toxicity of bexarotene 1% gel in healthy women at elevated 
risk for breast cancer. A phase I dose escalation trial was designed to test the safety of three different dose levels 
and ensure the lowest dose level is safe prior to enrollment into the second dose level and so forth. Please see 
Figure 1 for the dose escalation schema. DLT is defined as a grade 2 skin adverse event that persists for at least 
6 days or any grade 3 event or greater adverse event possibly, probably, or definitely related to the study drug. 
In addition, a DLT will be a grade 2 skin adverse event that recurs and persists for at least 3 days. The MTD 
will be defined as the highest dose level with at most 2 DLTs in 10 participants treated. A dose expansion group 
of additional 10 patients will be accrued at the MTD for the same treatment duration of 4 weeks with required 
baseline and post treatment biopsies to understand safety, toxicity, and penetration of bexarotene into the breast 
tissue.  
 
 
Figure 1: Dose Escalation Schema for Bexarotene 1% gel 
 
 

DCP Protocol Number MDA2016-08-02 
Protocol Version 14, Dated 4/27/2021 
 
DCP Protocol Template Version 8.5 
–37– 
08/31/2016 
 
 
 
13.2 
Randomization/Stratification  
 
A conservative modification of the standard “3+3” design will be applied. The first three participants will be 
assigned to the lowest dose level. New cohorts of 3-4 participants will not be treated until toxicity has been 
evaluated for all current participants for 4 weeks.  Group assignment algorithm is explained in Section 13.4. 
 
 
 
 
13.3 
Accrual and Feasibility 
 
Treatment will be initiated in 10 participants per group up to 40 participants. Participants found eligible but 
who withdraw without initiating treatment will be replaced and will not be followed or evaluable for DLTs. We 
plan to screen (consent) 60 participants to enroll (initiate treatment in) up to 40 participants.  Our estimated 
screen out rate after consent prior to study participation is approximately 25%. We anticipate accrual of approx. 
3 participants per month. Since accrual is done in groups of 3-4 participants, there will be a 4 week hold in 
accrual to assess for toxicity in the currently enrolled participants. Assuming that all dose levels are maximally 
accrued to, there will be 9 months of intentional hold on accrual to assess for safety and toxicity. Therefore, it 
will take approximately 21 months to complete accrual to the three dose levels and an additional 4 months to 
accrue to the dose expansion cohort. 
 
 
 
13.4 
Primary Objective, Endpoint(s), Analysis Plan 
 
The primary objective of this study is to determine the safety and toxicity of topical 1% bexarotene gel 
application to the breasts of healthy women at high risk for breast cancer for a duration of 4 weeks.  Women 
with ADH, ALH, LCIS, breast cancer survivors (DCIS or invasive) ≥ 5 years from their diagnosis, BRCA 1/2 
mutation carriers, and women with elevated risk for breast cancer ≥1.7% in 5 years or lifetime risk ≥20%  will 
be recruited. Three dose levels are considered (10mg every other day, 10mg daily, and 20mg daily). Dose 
Limiting Toxicity (DLT) is defined as a grade 2 skin adverse event that persists for at least 6 days or any grade 
3 or greater adverse event possibly, probably, definitely related to the study drug. In addition, a DLT will be a 
grade 2 skin adverse event that recurs and persists for at least 3 days. A conservative modification of the 
standard “3+3” design will be applied. The first cohort of 3 participants will be treated at the first dose level 
(10mg every other day). New cohort of participants will not be treated until toxicity has been fully evaluated 
for all current participants for 4 weeks. We will add another 4 participants when only 1 or less participants 
experience DLT in 6 treated participants.  We will only escalate dose to the next higher level when 20% or less 
of total participants experience DLT. At any dose level, the algorithm is as follows: 
 
(1) If 0 or 1 out of 3 participants experience DLTs (≤1/3), an additional cohort of 3 participants will be 
treated at the same dose level. If total number of participants experiencing DLT at that dose level is 1 
or less out of 6 (≤ 1/6), we will enroll another 4 participants the same dose level.  
(2) If at any time 2 or more participants experiences DLTs in 3 or 6 participants (≥ 2/3 or ≥ 2/6) or 3 or 
more participants experience DLT in 10 participants (≥3/10), then the dose escalation will stop, and the 
next lower dose will be considered as the maximum tolerated dose (MTD).  
(3) In 10 participants at each dose level, if we observe 2 or less DLTs, a cohort of 3 participants will be 
treated at the next higher level.  If 3 or more in 10 participants experience DLT, we will stop accrual to 
that level and above, and claim the regimen as to be too toxic for that level or above. 
 

DCP Protocol Number MDA2016-08-02 
Protocol Version 14, Dated 4/27/2021 
 
DCP Protocol Template Version 8.5 
–38– 
08/31/2016 
 
 
MTD is defined the highest dose level with at most 2 participants with DLTs in 10 participants treated.  
 
Once MTD is identified, we will enroll another 10 participants into MTD and these participants will have 
mandatory biopsies before and after 4 weeks of treatment.  We will continuously monitor aggregate DLTs in 
these participants together with the 10 participants treated during the dose escalation part of the study.  If at any 
time the posterior probability of observing a DLT rate of at least 20% exceeds 70%, i.e., Pr(DLT rate >=0.20 | 
Data) >70%, given the prior of the DLT rate of beta (0.2, 0.8), we will stop the trial and claim the dose is too 
toxic.    Given the above rule the boundaries for early stopping due to excessive DLT are Total Number of 
Participants with DLTs/Total Number of Participants >= 4/11~14, 5/15~19, and 6/20.   Combining with the 
boundaries during dose escalation phase, i.e., stop accrual at the dose level if Total Number of Participants with 
DLTs/Total Number of Participants >= 2/3, 2/6, 3/10, 4/11~14, 5/15~19, and 6/20, the early stopping 
probability for this level will be 15%, 51%, 82% if the true DLT rate is 0.10, 0.20, and 0.30, respectively. 
 
Given that there are 3 dose levels and 10 participants enrolled and treated at each level, and 10 additional 
patients at MTD, it is anticipated that 40 participants will be treated and up to 40 will be evaluable at the end 
of this study.  
 
 
At the end of the study, the toxicity data will be summarized for each dose level using frequency tabulation.  
The compliance of treatment application for each dose level will be presented using descriptive statistics. 
 
 
13.5  Secondary Objectives, Endpoints, Analysis Plans 
 
Secondary Objectives:  
 
1. To detect bexarotene concentration in the serum at baseline and at 4 weeks of treatment. 
2. To detect bexarotene concentration in the breast tissue at 4 weeks of treatment in the dose escalation 
group. 
3. To investigate the effects of topical bexarotene on serum biomarkers  
We will determine the change from the baseline in:  
i. 
Lipid Biomarkers (Total Cholesterol, triglycerides, LDL, HDL) 
ii. 
Thyroid Function Biomarkers (Thyroid Stimulating Hormone (TSH), T4, T3) 
iii. 
Calcium 
 
These measurements will be summarized using mean, standard deviation and median (range) for continuous 
variables at each time point. Wilcoxon rank-sum test may be used to examine the difference of continuous 
variables between participants’ characteristics groups. Participants’ demographic characteristics will be 
compared between different dose levels by Wilcoxon rank-sum and Fisher’s exact test for continuous and 
categorical variables, respectively.  In order to explore the changes over time, values of bexarotene 
concentration and biomarkers in serum will be plotted as functions of time (baseline, week 1, week 2, and week 
4). Linear mixed effect model will be applied to model the biomarker change over time for all participants.  
Appropriate transformation and regression model will be used to ensure the model fit. Estimated bexarotene 
concentration mean in the breast tissue at 4 weeks will be calculated along with a 95% confidence interval. 
Other statistical methods may be applied when appropriate. 
 
 
13.6 
Reporting and Exclusions 
 

DCP Protocol Number MDA2016-08-02 
Protocol Version 14, Dated 4/27/2021 
 
DCP Protocol Template Version 8.5 
–39– 
08/31/2016 
 
Every reasonable attempt will be made to recover any missing data.  If any data for the primary efficacy measure 
remains missing then the change of the primary endpoint for will not be calculated and the participant will not 
be evaluable for the primary endpoint.  However any available data from other time points will be included in 
the repeated measure analysis.   
 
 
13.7 
Evaluation of Toxicity 
 
All participants will be evaluable for toxicity from the time of their first dose of bexarotene gel.  The grade, 
attribution, onset and resolve date of all toxicities will be recorded and summarized for each dose level at the 
end of the study.  
 
 
13.8 
Evaluation of Response 
 
All participants included in the study must be assessed for response to intervention, even if there are major 
protocol deviations or if they are ineligible.  
 
All of the participants who met the eligibility criteria (with the possible exception of those who did not   receive 
study agent) will be included in the main analysis. All conclusions regarding secondary efficacy measures 
requiring breast biopsies will be based on eligible participants selecting this option. 
 
Subanalyses may be performed on the subsets of participants, excluding those for whom major protocol 
deviations have been identified (e.g., early death due to other reasons, early discontinuation of intervention, 
major protocol violations, etc.). However, subanalyses may not serve as the basis for drawing conclusions 
concerning efficacy, and the reasons for excluding participants from the analysis should be clearly reported. 
For all measurements of response, the 95% confidence intervals should also be provided. 
 
 
13.9 
Interim Analysis 
 
There is continual interim analysis in a modified 3+3 design for this study. 
 
 
13.10 Ancillary Studies  
 
No additional ancillary studies are planned. 
 
 
14. 
ETHICAL AND REGULATORY CONSIDERATIONS 
 
14.1 
Form FDA 1572 
 
Prior to initiating this study, the Protocol Lead Investigator at the Lead or Participating Organization(s) will 
provide a signed Form FDA 1572 stating that the study will be conducted in compliance with regulations for 
clinical investigations and listing the investigators, at each site that will participate in the protocol. All personnel 
directly involved in the performance of procedures required by the protocol and the collection of data should 
be listed on Form FDA 1572. 
 
14.2 
Other Required Documents 
 

DCP Protocol Number MDA2016-08-02 
Protocol Version 14, Dated 4/27/2021 
 
DCP Protocol Template Version 8.5 
–40– 
08/31/2016 
 
14.2.1 Current (within two years) CV or biosketch for all study personnel listed on the Form FDA 1572 and 
Delegation of Tasks form for the Lead Organization and all Participating Organizations.  
 
14.2.2 Current medical licenses (where applicable) for all study personnel listed on Form FDA 1572 and 
Delegation of Tasks form for the Lead Organization and all Participating Organizations. 
 
14.2.3 Lab certification (e.g., CLIA, CAP) and lab normal ranges for all labs listed on Form FDA 1572 for the 
Lead Organization and all Participating Organizations. 
 
14.2.4 Documentation of training in “Protection of Human Research Subjects” for all study personnel listed 
on the FDA Form 1572 and Delegation of Tasks form for the Lead Organization and all Participating 
Organizations. 
 
14.2.5 Documentation of Federalwide Assurance (FWA) number for the Lead Organization and all 
Participating Organizations. 
 
14.2.6 Signed Investigator’s Brochure/Package Insert acknowledgement form 
 
14.2.7 Delegation of Tasks form for the Lead Organization and all Participating Organizations signed by the 
Principal Investigator for each site and initialed by all study personnel listed on the form 
 
14.2.8 Signed and dated NCI, DCP Financial Disclosure Form for all study personnel listed on Form FDA 
1572 for the Lead Organization and all Participating Organizations 
 
 
14.3 
Institutional Review Board Approval 
 
Prior to initiating the study and receiving agent, the Investigators at the Lead Organization and the Participating 
Organization(s) must obtain written approval to conduct the study from the appropriate IRB. Should changes 
to the study become necessary, protocol amendments will be submitted to the DCP PIO according to DCP 
Amendment Guidelines. The DCP-approved amended protocol must be approved by the IRB prior to 
implementation 
 
 
14.4 
Informed Consent 
 
All potential study participants will be given a copy of the IRB-approved Informed Consent to review. The 
investigator will explain all aspects of the study in lay language and answer all questions regarding the study. 
If the participant decides to participate in the study, he/she will be asked to sign and date the Informed Consent 
document. The study agent(s) will not be released to a participant who has not signed the Informed Consent 
document. Subjects who refuse to participate or who withdraw from the study will be treated without prejudice. 
 
Participants must be provided the option to allow the use of blood samples, other body fluids, and tissues 
obtained during testing, operative procedures, or other standard medical practices for further research purposes. 
If applicable, statement of this option may be included within the informed consent document or may be 
provided as an addendum to the consent. A Model Consent Form for Use of Tissue for Research is available 
through a link in the DCP website. 
 
Prior to study initiation, the informed consent document must be reviewed and approved by NCI, DCP, the 
Consortium Lead Organization, and the IRB at each Organization at which the protocol will be implemented. 

DCP Protocol Number MDA2016-08-02 
Protocol Version 14, Dated 4/27/2021 
 
DCP Protocol Template Version 8.5 
–41– 
08/31/2016 
 
Any subsequent changes to the informed consent must be approved by NCI, DCP, the Consortium Lead 
Organization’s IRB, and then submitted to each organization’s IRB for approval prior to initiation. 
 
 
14.5 
Submission of Regulatory Documents 
 
All regulatory documents are collected by the CLO and reviewed for completeness and accuracy. Once the 
CLO has received complete and accurate documents from the Site, the CLO will forward the regulatory 
documents to DCP’s Regulatory Contractor: 
 
 
Paper Document/CD-ROM Submissions: 
 
Regulatory Affairs Department 
 
CCS Associates, Inc. 
 
2001 Gateway Place, Suite 350 West 
 
San Jose, CA 95110 
 
Phone: 650-691-4400 
 
Fax: 650-691-4410 
 
E-mail Submissions: 
 
regulatory@ccsainc.com 
 
Regulatory documents that do not require an original signature may be sent electronically to the CLO for review, 
which will then be electronically forwarded to DCP’s Regulatory Contractor. 
 
14.6 
Other 
 
This trial will be conducted in compliance with the protocol, Good Clinical Practice (GCP), and the applicable 
regulatory requirements. 
 
 
15. 
FINANCING, EXPENSES, AND/OR INSURANCE 
 
Participants will not be responsible for non-standard of care costs of this study. Study agent will be provided at 
no cost to the participant. Participants in the dose escalation cohort who choose to participate in an optional 
core breast biopsy at the end of study treatment will receive compensation for additional expenses associated 
with the biopsy, such as additional travel expenses, time missed from work or other expenses associated with 
the biopsy visit. All participants in the dose expansion cohort will have a core breast biopsy at end of treatment 
and will receive compensation for additional expenses associated with the biopsy, such as additional travel 
expenses, time missed from work or other expenses associated with the biopsy visit.  If, as a result of 
participation in this study, an individual experiences injury from known or unknown risks of the research 
procedures as described in the informed consent, immediate medical care and treatment, including 
hospitalization, if necessary, will be available.  No monetary compensation is available for the costs of medical 
treatment for an injury, thus, the participant will be responsible for the costs of such medical treatment, either 
directly or through their medical insurance and/or other forms of medical coverage.  
 
 

DCP Protocol Number MDA2016-08-02 
Protocol Version 14, Dated 4/27/2021 
 
DCP Protocol Template Version 8.5 
–42– 
08/31/2016 
 
REFERENCES 
 
1. 
Theodosiou M, Laudet V, Schubert M. From carrot to clinic: an overview of the retinoic acid 
signaling pathway. Cellular and molecular life sciences : CMLS. 2010;67(9):1423-45. doi: 10.1007/s00018-
010-0268-z. PubMed PMID: 20140749. 
2. 
Bushue N, Wan YJ. Retinoid pathway and cancer therapeutics. Advanced drug delivery reviews. 
2010;62(13):1285-98. doi: 10.1016/j.addr.2010.07.003. PubMed PMID: 20654663; PMCID: 2991380. 
3. 
Tang XH, Gudas LJ. Retinoids, retinoic acid receptors, and cancer. Annual review of pathology. 
2011;6:345-64. doi: 10.1146/annurev-pathol-011110-130303. PubMed PMID: 21073338. 
4. 
Duvic M, Martin AG, Kim Y, Olsen E, Wood GS, Crowley CA, Yocum RC, Worldwide Bexarotene 
Study G. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or 
persistent early-stage cutaneous T-cell lymphoma. Archives of dermatology. 2001;137(5):581-93. PubMed 
PMID: 11346336. 
5. 
Breneman D, Duvic M, Kuzel T, Yocum R, Truglia J, Stevens VJ. Phase 1 and 2 trial of bexarotene 
gel for skin-directed treatment of patients with cutaneous T-cell lymphoma. Archives of dermatology. 
2002;138(3):325-32. PubMed PMID: 11902983. 
6. 
Talpur R, Vu J, Bassett R, Stevens V, Duvic M. Phase I/II randomized bilateral half-head comparison 
of topical bexarotene 1% gel for alopecia areata. Journal of the American Academy of Dermatology. 
2009;61(4):592 e1-9. doi: 10.1016/j.jaad.2009.02.037. PubMed PMID: 19682769. 
7. 
Medina D, Kittrell F, Hill J, Zhang Y, Hilsenbeck SG, Bissonette R, Brown PH. Prevention of 
tumorigenesis in p53-null mammary epithelium by rexinoid bexarotene, tyrosine kinase inhibitor gefitinib, 
and celecoxib. Cancer prevention research. 2009;2(2):168-74. doi: 10.1158/1940-6207.CAPR-08-0107. 
PubMed PMID: 19174577; PMCID: 2995265. 
8. 
Li Y, Zhang Y, Hill J, Kim HT, Shen Q, Bissonnette RP, Lamph WW, Brown PH. The rexinoid, 
bexarotene, prevents the development of premalignant lesions in MMTV-erbB2 mice. British journal of 
cancer. 2008;98(8):1380-8. doi: 10.1038/sj.bjc.6604320. PubMed PMID: 18362934; PMCID: 2361704. 
9. 
Brown P, Arun, B., A. Miller, C. Isaacs, C. Gutierrez, J. Huang, S. Mohsin, I. Migliaccio, N. Sneige, 
H. Kim, K. Sexton, S. Hilsenbeck, W. Lamph, A. Negro-Vilar, K. Johnson, and R. Elledge. Phase II trial of 
bexarotene in women at high risk of breast cancer: Comparison of protein and RNA biomarkers. Cancer 
prevention research. 2008;1(7 Suppl):CN04-. 
10. 
Dragnev KH, Ma T, Cyrus J, Galimberti F, Memoli V, Busch AM, Tsongalis GJ, Seltzer M, 
Johnstone D, Erkmen CP, Nugent W, Rigas JR, Liu X, Freemantle SJ, Kurie JM, Waxman S, Dmitrovsky E. 
Bexarotene plus erlotinib suppress lung carcinogenesis independent of KRAS mutations in two clinical trials 
and transgenic models. Cancer prevention research. 2011;4(6):818-28. doi: 10.1158/1940-6207.CAPR-10-
0376. PubMed PMID: 21636548; PMCID: 3108499. 
11. 
Mauvais-Javis P, Baudot N, Castaigne D, Banzet P, Kuttenn F. trans-4-Hydroxytamoxifen 
concentration and metabolism after local percutaneous administration to human breast. Cancer research. 
1986;46(3):1521-5. PubMed PMID: 3943109. 
12. 
Rouanet P, Linares-Cruz G, Dravet F, Poujol S, Gourgou S, Simony-Lafontaine J, Grenier J, Kramar 
A, Girault J, Le Nestour E, Maudelonde T. Neoadjuvant percutaneous 4-hydroxytamoxifen decreases breast 
tumoral cell proliferation: a prospective controlled randomized study comparing three doses of 4-
hydroxytamoxifen gel to oral tamoxifen. Journal of clinical oncology : official journal of the American 
Society of Clinical Oncology. 2005;23(13):2980-7. doi: 10.1200/JCO.2005.06.064. PubMed PMID: 
15860853. 
13. 
Lee O, Page K, Ivancic D, Helenowski I, Parini V, Sullivan ME, Margenthaler JA, Chatterton RT, Jr., 
Jovanovic B, Dunn BK, Heckman-Stoddard BM, Foster K, Muzzio M, Shklovskaya J, Skripkauskas S, 
Kulesza P, Green D, Hansen NM, Bethke KP, Jeruss JS, Bergan R, Khan SA. A randomized phase II 
presurgical trial of transdermal 4-hydroxytamoxifen gel versus oral tamoxifen in women with ductal 
carcinoma in situ of the breast. Clin Cancer Res. 2014;20(14):3672-82. doi: 10.1158/1078-0432.CCR-13-
3045. PubMed PMID: 25028506; PMCID: PMC4101910. 
 
 

DCP Protocol Number MDA2016-08-02 
Protocol Version 14, Dated 4/27/2021 
 
DCP Protocol Template Version 8.5 
–43– 
08/31/2016 
 
APPENDIX A 
Performance Status Criteria 
 
ECOG Performance Status Scale 
Grade Descriptions 
0 
Normal activity. Fully active, able to carry 
on all pre-disease performance without 
restriction. 
1 
Symptoms, but ambulatory. Restricted in 
physically 
strenuous 
activity, 
but 
ambulatory and able to carry out work of a 
light or sedentary nature (e.g., light 
housework, office work). 
2 
In bed <50% of the time. Ambulatory and 
capable of all self-care, but unable to carry 
out any work activities. Up and about more 
than 50% of waking hours. 
3 
In bed >50% of the time. Capable of only 
limited self-care, confined to bed or chair 
more than 50% of waking hours. 
4 
100% bedridden. Completely disabled. 
Cannot carry on any self-care. Totally 
confined to bed or chair. 
5 
Dead. 
 
Karnofsky Performance Scale 
Percent 
Description 
100 
Normal, no complaints, no evidence of 
disease. 
90 
Able to carry on normal activity; minor 
signs or symptoms of disease. 
80 
Normal activity with effort; some signs 
or symptoms of disease. 
70 
Cares for self, unable to carry on normal 
activity or to do active work. 
60 
Requires occasional assistance, but is 
able to care for most of his/her needs. 
50 
Requires considerable assistance and 
frequent medical care. 
40 
Disabled, requires special care and 
assistance. 
30 
Severely 
disabled, 
hospitalization 
indicated. Death not imminent. 
20 
Very sick, hospitalization indicated. 
Death not imminent. 
10 
Moribund, fatal processes progressing 
rapidly. 
0 
Dead. 

DCP Protocol Number MDA2016-08-02 
Protocol Version 14, Dated 4/27/2021 
 
DCP Protocol Template Version 8.5 
–44– 
08/31/2016 
 
Appendix B 
 
GEL APPLICATION INSTRUCTIONS  
 
1. Flammable: do not apply near fire, flame or heat, or while smoking  
 
2. Apply the gel to your breast after bathing, preferably in the morning and at approximately the same time each 
day. Apply approximately 30 minutes after bathing when breast is completely dry. 
 
3. To apply, remove the cap from the bottle. When you use the bottle for the first time, you must prime it by 
pressing the pump fully several times until gel is dispensed (point the spout toward a sink or wastebasket and 
do not use the first dose, which may be incorrect).  
 
4. Once the bottle is primed, hold it in one hand and place the palm of your other hand under the pump to catch 
the gel. Be sure to press down completely on the pump and release it completely to dispense one dose of gel.  
 
5. Apply one dose of gel to one breast (dosage is indicated on the bottle label). Do not apply more or less than 
one dose to the breast. If you are assigned to the 20mg dose level (which requires two (2) pumps), be sure to 
release the pump completely between both actuations (pumps). Application of gel will always be to only one 
breast and the same breast each time. Do not alternate doses between breasts.  
 
6. If you accidentally pump more than is needed, please discard this dose and try again to get the correct dose. 
If you do discard pumped doses, please record this on your Gel Diary.  
 
7. Spread the gel evenly over the upper outer and upper inner quadrant of your breast, without rubbing. Start 
from above the areola and spread outwards to below the clavicle and up to the midsternal edge which is the 
midline of your chest. Avoid spreading the gel in the nipple and areola area of the breast. Avoid spreading the 
gel below the nipple or underneath the breast. Please see diagram below. 
 
 
 
8. Wash your hands immediately after applying the gel.  
 
9. Allow the gel on your breast to air dry for 2 minutes and then immediately cover with clothing (the gel is 
colorless and will not stain your clothing). Do not expose your bare breasts to sunlight or ultraviolet light 
(tanning beds) at any time while on the study. 
10. Do not apply any other cream, lotion or moisturizer to your breast immediately after application of the study 
drug.  
 
11. Do not wash your breast or immerse in water (bath, swim) for at least 4 hours following application of the 

DCP Protocol Number MDA2016-08-02 
Protocol Version 14, Dated 4/27/2021 
 
DCP Protocol Template Version 8.5 
–45– 
08/31/2016 
 
gel. If this is not possible, delay application of the gel that day until after immersion, and be sure to follow all 
the above instructions. If you regularly swim in the morning, it is better to apply the gel afterwards, after your 
shower.  
 
12. After use, replace the cap on the bottle.  
 
RECOMMENDATIONS:  
 
1. Be sure to apply after bathing or showering, each day during the study and preferably in the morning.  
 
2. You may use CeraVe moisturizing cream, a moisturizer that will be supplied to you, to apply to the same 
breast that you are applying the study gel. CeraVe moisturizing cream can be used in the evening or at least 4 
hours after study gel application so it will not interfere with absorption. CeraVe moisturizing cream can be 
applied daily to help with any skin redness. 
 
3. If you forget to apply a dose, do not double the dose to “catch up”.  
 
If you are applying the gel daily:  If your next dose is scheduled within the next 12 hours, it is best just to wait; 
if it is more than 12 hours until your next dose, apply the dose you missed and resume your normal dosing after 
that.  
 
If you are applying the gel every other day: If your next dose is scheduled within the next 24 hours, it is best 
just to wait; if it is more than 24 hours until your next dose, apply the dose you missed and resume your normal 
dosing after that.  
 
4. For the duration of the study, avoid contact between the application area and the skin of other individuals 
(i.e. your child, your sexual partner, or other persons). If necessary, skin contact is allowable after the breast 
has been washed. As noted above, you must wait at least 4 hours following application before washing the 
application area, otherwise, delay application until after washing and contact.  
5.  Avoid using sprays containing DEET (i.e. bug spray) to the treated area and limit vitamin A intake to <5000 
IU per day. 
 
6. Do not ingest or swallow the gel. For external use only.  
 
7. Please note the first and last day of use on the bottle label.  
 
8. If the pump doesn’t come back up correctly or if there’s no gel delivered when you press down on the pump, 
notify your doctor immediately. A replacement bottle will be shipped to you. 
 
9. After the end of study treatment, be sure to take back to your doctor all the gel bottles you have been given 
(even if empty or not used). This is very important for the success of the study.  
 
10. If any ulcerations, blisters or open areas start please notify the research team the next day for guidance. 
 
STORAGE INSTRUCTIONS:  
 
1. Keep your gel bottles in a cool room temperature- 59°F to 77°F.  
 
2. Keep the gel bottles out of the reach of children.  
 

DCP Protocol Number MDA2016-08-02 
Protocol Version 14, Dated 4/27/2021 
 
DCP Protocol Template Version 8.5 
–46– 
08/31/2016 
 
APPENDIX C 
 
Bexarotene Gel Diaries 
 
 
 

DCP Protocol Number MDA2016-08-02 
Protocol Version 14, Dated 4/27/2021 
 
DCP Protocol Template Version 8.5 
–47– 
08/31/2016 
 
 
Bexarotene Gel Diary [IRB Protocol #:                     ] 
 
Group 1 
 
PID: __ __ __ __ __ __ __ __ __ __ 
 
Amount of Agent Provided: Number of Canisters ______ 
 
Total Daily Dose: 10mg applied to one breast, every other day 
 
Pump actuations: Push the Pump 1 time 
 
Breast to Apply Gel: Right OR Left 
 
Number of Canisters Returned: ________ 
 
Visit#: ______ 
 
 
INSTRUCTIONS: 
 
1. Complete the diary daily.   
 
2. If you miss an application, do not take an extra application to “make up” for the missed application.   
 
If your next dose is scheduled within the next 24 hours, it is best just to wait; if it is more than 24 hours 
until your next dose, apply the dose you missed and resume your normal dosing after that.  
 
3. If you accidentally pump more than is needed for one breast, please discard this dose and try again to 
get correct dose. If you do discard pumped doses, please record this on your Gel Diary.   
 
4. Do not discard the gel canister.  Bring the canister and this diary to your next appointment. 
 
5. Store the study gel at home at room temperature and avoid extreme heat or cold during transportation 
from the clinic to home. 
 
6. If you experience any concerning side effects or changes in the texture of your skin (e.g., skin feels like 
sandpaper),  call ________________________(insert name of Study Coordinator or Study Nurse) at 
__________________(insert telephone number) or the study doctor, Dr. Parijatham Thomas at 713-
745-8040 for guidance. 
 
 
 

DCP Protocol Number MDA2016-08-02 
Protocol Version 14, Dated 4/27/2021 
 
DCP Protocol Template Version 8.5 
–48– 
08/31/2016 
 
Bexarotene Gel Diary Group 1 Continued 
 
Please Bring this Sheet and Empty Canister to Your Next Visit 
 
Day 
Date 
R or L Breast, 
OR Did not apply 
Initials 
Did you experience any symptoms, if 
“Yes” list below 
 
List # of discarded pumps of gel here 
Week 1 
Apply 1 pump to the breast every 
other day 
1 
 
□R              □L 
□Did not apply 
 
 
2 
 
□R             □L 
□Did not apply 
 
 
3 
 
□R              □L 
□Did not apply 
 
 
4 
 
□R              □L 
□Did not apply 
 
 
5 
 
□R              □L 
□Did not apply 
 
 
6 
 
□R              □L 
□Did not apply 
 
 
7 
 
□R              □L 
□Did not apply 
 
 
Week 2 
Apply 1 pump to the breast every 
other day 
8 
 
□R              □L 
□Did not apply 
 
 
9 
 
□R              □L 
□Did not apply 
 
 
10 
 
□R              □L 
□Did not apply 
 
 
11 
 
□R              □L 
□Did not apply 
 
 
12 
 
□R              □L 
□Did not apply 
 
 
13 
 
□R              □L 
□Did not apply 
 
 
14 
 
□R              □L 
□Did not apply 
 
 
Week 3 
Apply 1 pump to the breast every 
other day 
15 
 
□R              □L 
□Did not apply 
 
 
16 
 
□R              □L 
□Did not apply 
 
 
17 
 
□R              □L 
□Did not apply 
 
 
18 
 
□R              □L 
□Did not apply 
 
 
19 
 
□R              □L 
□Did not apply 
 
 
20 
 
□R              □L 
□Did not apply 
 
 
21 
 
□R              □L 
□Did not apply 
 
 

DCP Protocol Number MDA2016-08-02 
Protocol Version 14, Dated 4/27/2021 
 
DCP Protocol Template Version 8.5 
–49– 
08/31/2016 
 
 
 
 
 
Participant’s Signature: _______________________________________ 
Date: ___________________ 
 
Reviewer’s Signature: ________________________________________ 
Date: ___________________ 
 
 
Comments: 
______________________________________________________________________________________________
______________________________________________________________________________________________
______________________________________________________________________________________________
______________________________________________________________ 
 
 
 
 
Day 
Date 
R or L Breast,  
OR Did not apply 
Initials 
Did you experience any symptoms, if 
“Yes” list below 
 
List # of discarded pumps of gel here 
Week 4 
Apply 1 pump to the breast every other 
day 
22 
 
□R              □L 
□Did not apply 
 
 
 
23 
 
□R              □L 
□Did not apply 
 
 
24 
 
□R              □L 
□Did not apply 
 
 
25 
 
□R              □L 
□Did not apply 
 
 
26 
 
□R              □L 
□Did not apply 
 
 
27 
 
□R              □L 
□Did not apply 
 
 
28 
 
□R              □L 
□Did not apply 
 
 
 
29 
 
□R              □L 
□Did not apply 
 
 
30 
 
□R              □L 
□Did not apply 
 
 

DCP Protocol Number MDA2016-08-02 
Protocol Version 14, Dated 4/27/2021 
 
DCP Protocol Template Version 8.5 
–50– 
08/31/2016 
 
Bexarotene Gel Diary [IRB Protocol #:                     ] 
 
Group 2 
 
PID: __ __ __ __ __ __ __ __ __ __ 
 
Amount of Agent Provided: Number of Canisters ______ 
 
Total Daily Dose:  
 
Week 1: 10mg applied to one breast, every other day  
Push the Pump 1 time 
 
Weeks 2-4: 10mg applied to one breast, every day 
Push the Pump 1 time 
 
Breast to Apply Gel: Right OR Left 
 
Number of Canisters Returned: ________ 
 
Visit#: ______ 
 
 
INSTRUCTIONS: 
 
1. Complete the diary daily.   
 
2. If you miss an application, do not take an extra application to “make up” for the missed application.   
 
If you are applying the gel daily:  If your next dose is scheduled within the next 12 hours, it is best just 
to wait; if it is more than 12 hours until your next dose, apply the dose you missed and resume your 
normal dosing after that.  
 
If you are applying the gel every other day: If your next dose is scheduled within the next 24 hours, it 
is best just to wait; if it is more than 24 hours until your next dose, apply the dose you missed and 
resume your normal dosing after that.  
 
3. If you accidentally pump more than is needed for one breast, please discard this dose and try again to 
get correct dose. If you do discard pumped doses, please record this on your Gel Diary.   
 
4. Do not discard the gel canister.  Bring the canister and this diary to your next appointment. 
 
5. Store the study gel at home at room temperature and avoid extreme heat or cold during transportation 
from the clinic to home. 
 
6. If you experience any concerning side effects or changes in the texture of your skin (e.g., skin feels like 
sandpaper),  call ________________________(insert name of Study Coordinator or Study Nurse) at 
__________________(insert telephone number) or the study doctor, Dr. Parijatham Thomas at 713-
745-8040 for guidance..  
 

DCP Protocol Number MDA2016-08-02 
Protocol Version 14, Dated 4/27/2021 
 
DCP Protocol Template Version 8.5 
–51– 
08/31/2016 
 
Bexarotene Gel Diary Group 2 Continued 
Please Bring this Sheet and Empty Canister to Your Next Visit 
 
 
 
 
Day 
Date 
R or L Breast,  OR 
Did not apply 
Initials 
Did you experience any symptoms, if 
“Yes” list below 
 
List # of discarded pumps of gel here 
Week 1 
Apply 1 pump to the breast every 
other day 
1 
 
□R              □L 
□Did not apply 
 
 
2 
 
□R              □L 
□Did not apply 
 
 
3 
 
□R              □L 
□Did not apply 
 
 
4 
 
□R              □L 
□Did not apply 
 
 
5 
 
□R              □L 
□Did not apply 
 
 
6 
 
□R              □L 
□Did not apply 
 
 
7 
 
□R              □L 
□Did not apply 
 
 
Week 2 
Apply 1 pump to the breast every day 
8 
 
□R              □L 
□Did not apply 
 
 
9 
 
□R              □L 
□Did not apply 
 
 
10 
 
□R              □L 
□Did not apply 
 
 
11 
 
□R              □L 
□Did not apply 
 
 
12 
 
□R              □L 
□Did not apply 
 
 
13 
 
□R              □L 
□Did not apply 
 
 
14 
 
□R              □L 
□Did not apply 
 
 
Week 3 
Apply 1 pump to the breast every day 
15 
 
□R              □L 
□Did not apply 
 
 
16 
 
□R              □L 
□Did not apply 
 
 
17 
 
□R              □L 
□Did not apply 
 
 
18 
 
□R              □L 
□Did not apply 
 
 
19 
 
□R              □L 
□Did not apply 
 
 
20 
 
□R              □L 
□Did not apply 
 
 
21 
 
□R              □L 
□Did not apply 
 
 

DCP Protocol Number MDA2016-08-02 
Protocol Version 14, Dated 4/27/2021 
 
DCP Protocol Template Version 8.5 
–52– 
08/31/2016 
 
 
 
 
Participant’s Signature: _______________________________________ 
Date: ___________________ 
 
Reviewer’s Signature: ________________________________________ 
Date: ___________________ 
 
 
Comments: 
______________________________________________________________________________________________
______________________________________________________________________________________________
______________________________________________________________________________________________
______________________________________________________________ 
 
 
 
 
 
Day 
Date 
R or L Breast, OR  
Did not apply 
Initials 
Did you experience any symptoms, if 
“Yes” list below 
 
List # of discarded pumps of gel here 
Week 4 
Apply 1 pump to the breast every day 
22 
 
□R              □L 
□Did not apply 
 
 
23 
 
□R              □L 
□Did not apply 
 
 
24 
 
□R              □L 
□Did not apply 
 
 
25 
 
□R              □L 
□Did not apply 
 
 
26 
 
□R              □L 
□Did not apply 
 
 
27 
 
□R              □L 
□Did not apply 
 
 
28 
 
□R              □L 
□Did not apply 
 
 
 
29 
 
□R              □L 
□Did not apply 
 
 
30 
 
□R              □L 
□Did not apply 
 
 

DCP Protocol Number MDA2016-08-02 
Protocol Version 14, Dated 4/27/2021 
 
DCP Protocol Template Version 8.5 
–53– 
08/31/2016 
 
Bexarotene Gel Diary [IRB Protocol #:                     ] 
 
Group 3 
 
PID: __ __ __ __ __ __ __ __ __ __ 
 
Amount of Agent Provided: Number of Canisters ______ 
 
Total Daily Dose:  
 
Week 1: 10mg applied to one breast, every other day  
Push the Pump 1 time 
 
Week 2: 10mg applied to one breast, every day 
Push the Pump 1 time 
 
Weeks 3-4: 20mg applied to one breast, every day 
Push the Pump 2 times 
 
Breast to Apply Gel: Right OR Left 
 
Number of Canisters Returned: ________ 
 
Visit#: ______ 
 
INSTRUCTIONS: 
 
1. Complete the diary daily.   
 
2. If you miss an application, do not take an extra application to “make up” for the missed application.   
 
If you are applying the gel daily:  If your next dose is scheduled within the next 12 hours, it is best just to 
wait; if it is more than 12 hours until your next dose, apply the dose you missed and resume your normal 
dosing after that.  
 
If you are applying the gel every other day: If your next dose is scheduled within the next 24 hours, it is 
best just to wait; if it is more than 24 hours until your next dose, apply the dose you missed and resume 
your normal dosing after that.  
 
3. If you accidentally pump more than is needed for one breast, please discard this dose and try again to get 
correct dose. If you do discard pumped doses, please record this on your Gel Diary.   
 
4. Do not discard the gel canisters.  Bring the canisters and this diary to your next appointment. 
 
5. Store the study gel at home at room temperature and avoid extreme heat or cold during transportation from 
the clinic to home. 
 
6. If you experience any concerning side effects or changes in the texture of your skin (e.g., skin feels like 
sandpaper),  call ________________________(insert name of Study Coordinator or Study Nurse) at 
__________________(insert telephone number) or the study doctor, Dr. Parijatham Thomas at 713-745-
8040 for guidance. 

DCP Protocol Number MDA2016-08-02 
Protocol Version 14, Dated 4/27/2021 
 
DCP Protocol Template Version 8.5 
–54– 
08/31/2016 
 
 
Bexarotene Gel Diary Group 3 Continued 
 
Please Bring this Sheet and Empty Canisters to Your Next Visit 
 
 
 
 
 
 
Day 
Date 
R or L 
Breast 
Initials 
# of pumps 
Did you experience any 
symptoms, if “Yes” list below 
 
List # of discarded doses here 
Week 1 
Apply 1 pump to the breast 
every other day 
1 
 
 
 
____     or   □Did not apply 
 
2 
 
 
 
____     or   □Did not apply 
 
3 
 
 
 
____     or   □Did not apply 
 
4 
 
 
 
____     or   □Did not apply 
 
5 
 
 
 
____     or   □Did not apply 
 
6 
 
 
 
____     or   □Did not apply 
 
7 
 
 
 
____     or   □Did not apply 
 
Week 2 
Apply 1 pump to the breast 
every day 
8 
 
 
 
____     or   □Did not apply 
 
9 
 
 
 
____     or   □Did not apply 
 
10 
 
 
 
____     or   □Did not apply 
 
11 
 
 
 
____     or   □Did not apply 
 
12 
 
 
 
____     or   □Did not apply 
 
13 
 
 
 
____     or   □Did not apply 
 
14 
 
 
 
____     or   □Did not apply 
 
Week 3 
Apply 2 pumps to the breast 
every day 
15 
 
 
 
____     or   □Did not apply 
 
16 
 
 
 
____     or   □Did not apply 
 
17 
 
 
 
____     or   □Did not apply 
 
18 
 
 
 
____     or   □Did not apply 
 
19 
 
 
 
____     or   □Did not apply 
 
20 
 
 
 
____     or   □Did not apply 
 
21 
 
 
 
____     or   □Did not apply 
 

DCP Protocol Number MDA2016-08-02 
Protocol Version 14, Dated 4/27/2021 
 
DCP Protocol Template Version 8.5 
–55– 
08/31/2016 
 
 
 
 
Participant’s Signature: _______________________________________ 
Date: ___________________ 
 
Reviewer’s Signature: ________________________________________ 
Date: ___________________ 
 
 
Comments: 
______________________________________________________________________________________________
______________________________________________________________________________________________
______________________________________________________________________________________________
______________________________________________________________ 
 
 
 
 
Day 
Date 
R or L 
Breast 
Initials 
# of pumps 
Did you experience any 
symptoms, if “Yes” list below 
 
List # of discarded doses 
here 
Week 4 
Apply 2 pumps to the breast 
every day 
22 
 
 
 
____     or   □Did not apply 
 
23 
 
 
 
____     or   □Did not apply 
 
24 
 
 
 
_____     or   □Did not apply 
 
25 
 
 
 
_____     or   □Did not apply 
 
26 
 
 
 
_____     or   □Did not apply 
 
27 
 
 
 
_____     or   □Did not apply 
 
28 
 
 
 
_____     or   □Did not apply 
 
 
29 
 
 
 
_____     or   □Did not apply 
 
30 
 
 
 
_____     or   □Did not apply 
 

DCP Protocol Number MDA2016-08-02 
Protocol Version 14, Dated 4/27/2021 
 
DCP Protocol Template Version 8.5 
–56– 
08/31/2016 
 
 
Bexarotene Gel Diary [IRB Protocol #:                     ] 
 
Dose Expansion Group 
 
PID: __ __ __ __ __ __ __ __ __ __ 
 
Amount of Agent Provided: Number of Canisters ______ 
 
Total Daily Dose: 10mg applied to one breast, every other day 
 
Pump actuations: Push the Pump 1 time 
 
Breast to Apply Gel: Right OR Left 
 
Number of Canisters Returned: ________ 
 
Visit#: ______ 
 
 
INSTRUCTIONS: 
 
1. Complete the diary daily.   
 
2. If you miss an application, do not take an extra application to “make up” for the missed application.   
 
If your next dose is scheduled within the next 24 hours, it is best just to wait; if it is more than 24 hours 
until your next dose, apply the dose you missed and resume your normal dosing after that.  
 
3. If you accidentally pump more than is needed for one breast, please discard this dose and try again to 
get correct dose. If you do discard pumped doses, please record this on your Gel Diary.   
 
4. Do not discard the gel canister.  Bring the canister and this diary to your next appointment. 
 
5. Store the study gel at home at room temperature and avoid extreme heat or cold during transportation 
from the clinic to home. 
 
6. If you experience any concerning side effects or changes in the texture of your skin (e.g., skin feels like 
sandpaper),  call ________________________(insert name of Study Coordinator or Study Nurse) at 
__________________(insert telephone number) or the study doctor, Dr. Parijatham Thomas at 713-
745-8040 for guidance. 
 
 
 

DCP Protocol Number MDA2016-08-02 
Protocol Version 14, Dated 4/27/2021 
 
DCP Protocol Template Version 8.5 
–57– 
08/31/2016 
 
Bexarotene Gel Diary: Dose Expansion Group (Continued) 
 
Please Bring this Sheet and Empty Canister to Your Next Visit 
 
Day 
Date 
R or L Breast, 
OR Did not apply 
Initials 
Did you experience any symptoms, if 
“Yes” list below 
 
List # of discarded pumps of gel here 
Week 1 
Apply 1 pump to the breast every 
other day 
1 
 
□R              □L 
□Did not apply 
 
 
2 
 
□R             □L 
□Did not apply 
 
 
3 
 
□R              □L 
□Did not apply 
 
 
4 
 
□R              □L 
□Did not apply 
 
 
5 
 
□R              □L 
□Did not apply 
 
 
6 
 
□R              □L 
□Did not apply 
 
 
7 
 
□R              □L 
□Did not apply 
 
 
Week 2 
Apply 1 pump to the breast every 
other day 
8 
 
□R              □L 
□Did not apply 
 
 
9 
 
□R              □L 
□Did not apply 
 
 
10 
 
□R              □L 
□Did not apply 
 
 
11 
 
□R              □L 
□Did not apply 
 
 
12 
 
□R              □L 
□Did not apply 
 
 
13 
 
□R              □L 
□Did not apply 
 
 
14 
 
□R              □L 
□Did not apply 
 
 
Week 3 
Apply 1 pump to the breast every 
other day 
15 
 
□R              □L 
□Did not apply 
 
 
16 
 
□R              □L 
□Did not apply 
 
 
17 
 
□R              □L 
□Did not apply 
 
 
18 
 
□R              □L 
□Did not apply 
 
 
19 
 
□R              □L 
□Did not apply 
 
 
20 
 
□R              □L 
□Did not apply 
 
 
21 
 
□R              □L 
□Did not apply 
 
 

DCP Protocol Number MDA2016-08-02 
Protocol Version 14, Dated 4/27/2021 
 
DCP Protocol Template Version 8.5 
–58– 
08/31/2016 
 
 
 
 
 
Participant’s Signature: _______________________________________ 
Date: ___________________ 
 
Reviewer’s Signature: ________________________________________ 
Date: ___________________ 
 
 
Comments: 
______________________________________________________________________________________________
______________________________________________________________________________________________
______________________________________________________________________________________________
______________________________________________________________ 
 
 
 
 
 
 
Day 
Date 
R or L Breast,  
OR Did not apply 
Initials 
Did you experience any symptoms, if 
“Yes” list below 
 
List # of discarded pumps of gel here 
Week 4 
Apply 1 pump to the breast every other 
day 
22 
 
□R              □L 
□Did not apply 
 
 
 
23 
 
□R              □L 
□Did not apply 
 
 
24 
 
□R              □L 
□Did not apply 
 
 
25 
 
□R              □L 
□Did not apply 
 
 
26 
 
□R              □L 
□Did not apply 
 
 
27 
 
□R              □L 
□Did not apply 
 
 
28 
 
□R              □L 
□Did not apply 
 
 
 
29 
 
□R              □L 
□Did not apply 
 
 
30 
 
□R              □L 
□Did not apply 
 
 

DCP Protocol Number MDA2016-08-02 
Protocol Version 14, Dated 4/27/2021 
 
DCP Protocol Template Version 8.5 
–59– 
08/31/2016 
 
APPENDIX D 
 
Alcohol and Tobacco Use Assessment Questionnaires – Baseline 
 
 

DCP Protocol Number MDA2016-08-02 
Protocol Version 14, Dated 4/27/2021 
 
DCP Protocol Template Version 8.5 
–60– 
08/31/2016 
 
ALCOHOL ASSESSMENT – BASELINE 
 
REGISTERING INSTITUTION 
 
_________________________ 
PARTICIPANT ID 
 
_________________ 
VISIT TYPE 
 
________________ 
VISIT DATE 
(MM/DD/YYYY) 
___ ___ / ___ ___ / ___ ___ ___ ___ 
 
Instructions: 
For the following questions about drinking alcoholic beverages, a drink means a 12 oz. beer, a 5 oz. 
glass of wine, or one and a half ounces of liquor. 
 
1. In your entire life, have you had at least 12 drinks of any kind of alcoholic beverage?  
 Yes 
 No (End) 
 Refused (End) 
 Don’t know/Not sure 
 
2. In the past 12 months, on average, how often did you drink any type of alcoholic beverage?  
 
________ (Enter the number of days you drank based on the timeframe checked below.  Enter 0 if you 
never drank and skip to Question 6.)  
 Week  
 Month 
 Year 
 Refused 
 Don’t know/Not sure 
 
3. In the past 12 months, on those days that you drank alcoholic beverages, on average, how many drinks   
did you have per day?  
________ (Enter the average number of drinks per day) 
 
 Refused 
 Don’t know/Not sure 
 
4. In the past 12 months, on how many days did you have 5 or more drinks of any alcoholic beverage?  
 
_________ (Enter the number of days you had 5 or more drinks, or enter 0 if none.) 
 Refused 
 Don’t know/Not sure 
 
5. Was there ever a time or times in your life when you drank 5 or more drinks of any kind of alcoholic 
beverage almost every day?  
 Yes 
 No  
 Refused 
 Don’t know/Not sure 
 
 

DCP Protocol Number MDA2016-08-02 
Protocol Version 14, Dated 4/27/2021 
 
DCP Protocol Template Version 8.5 
–61– 
08/31/2016 
 
 
6. If you do not currently drink alcoholic beverages, but did in the past, how long has it been since 
you last drank regularly?  
 
 Within the past month (0 to 1 month ago) 
 Between 1 and 3 months (1 to 3 months ago) 
 Between 3 and 6 months (3 to 6 months ago) 
 Between 6 and 12 months (6 to 12 months ago) 
 Between 1 and 5 years (1 to 5 years ago) 
 Between 5 and 15 years (5 to 15 years ago) 
 More than 15 years ago  
 Don’t know/Not sure 
 Never drank regularly 
 
7. At the heaviest point, either now or in the past, on the days when you drank, about how many drinks did 
you drink a day on the average?  
 
__________ (Enter the number of drinks a day) 
  
 Refused 
 Don’t know/Not sure 
 
8. How many years have you been drinking (or did drink) regularly?  
 
______ years 
 
 Refused 
 Don’t know/Not sure  
 
9. At what age did you begin drinking regularly?  
 
______ years of age  
 
 Refused 
 Don’t know/Not sure  
 
10. What type(s) of alcohol do you drink? (Mark ALL that apply) 
 
 Wine 
 Liquor 
 Beer 
 Wine cooler 
 
Signature of Individual Completing This Form___________________   Date  __ __ / __ __ / __ __ __ __ 
 
(MM/DD/YYYY) 
Name of Individual Completing This Form (please print) ______________________________________ 
 
 

DCP Protocol Number MDA2016-08-02 
Protocol Version 14, Dated 4/27/2021 
 
DCP Protocol Template Version 8.5 
–62– 
08/31/2016 
 
TOBACCO ASSESSMENT – BASELINE 
 
REGISTERING INSTITUTION 
 
_________________________ 
PARTICIPANT ID 
 
_________________ 
VISIT TYPE 
 
________________ 
VISIT DATE 
(MM/DD/YYYY) 
___ ___ / ___ ___ / ___ ___ ___ ___ 
 
 
Section A. Basic Cigarette Use Information 
 
1. Have you smoked at least 100 cigarettes (5 packs = 100 cigarettes) in your entire life? 
 
Yes  
 
 No → Skip to Section B 
 Don’t know/Not sure → Skip to Section B 
 
2. How old were you when you first smoked a cigarette (even one or two puffs)? 
 
_______ Years old  
 
3. How old were you when you first began smoking cigarettes regularly?   
 
_______ Years old  
  Check here if you have never smoked cigarettes regularly. 
 
4. How many total years have you smoked (or did you smoke) cigarettes? Do not count any time you may 
have stayed off cigarettes. 
 
______ Years (If you smoked less than one year, write “1.”)  
 
5. On average when you have smoked, about how many cigarettes do you (or did you) smoke a day? (A pack 
usually has 20 cigarettes in it).  
 
_____ Number of cigarettes per day 
 
6. Do you NOW smoke cigarettes?  
 
 Everyday 
 Some days 
 Not at all → Skip to question 8 
 
7.  How soon after you wake up do you smoke your first cigarette?  
 
  Within 30 minutes 
  After 30 minutes 
 
 

DCP Protocol Number MDA2016-08-02 
Protocol Version 14, Dated 4/27/2021 
 
DCP Protocol Template Version 8.5 
–63– 
08/31/2016 
 
 
8. How long has it been since you last smoked a cigarette (even one or two puffs)? 
 
First check which one of the following choices applies to you. Then, if applicable, write a number on the 
line 
for how many days, weeks, months, or years it has been since your last cigarette. 
 
 I smoked a cigarette today (at least one puff) 
 1-7 days → Number of days since last cigarette  ________ 
 Less than 1 month → Number of weeks since last cigarette  _________ 
 Less than 1 year → Number of months since last cigarette  __________ 
 More than 1 year → Number of years since last cigarette  ___________ 
 Don’t know/Don’t remember 
 
Section B. Use of Other Forms of Tobacco 
 
9.  Have you ever used other forms of tobacco, not including cigarettes? 
  
 Yes  
 No → Skip to Section C 
 
10. How often do you/did you use other forms of tobacco?  
 
 Every day → Number of times per day  ________ 
 Some days → Number of days _______ per 
 Week 
 Month 
Year 
 
11. Which of the following products have you ever used regularly? 
 Check all that apply  
 
 Cigarettes 
 E-cigarettes or other electronic nicotine delivery system 
 Traditional cigars, cigarillos or filtered cigars 
 Pipes 
 Hookah 
 Clove cigarettes or kreteks 
 Bidis  
 Smokeless tobacco, like dip, chew, or snuff 
 Snus 
 Paan with tobacco, gutka, zarda, khaini 
 Other, Please specify:___________________________ 
 
 

DCP Protocol Number MDA2016-08-02 
Protocol Version 14, Dated 4/27/2021 
 
DCP Protocol Template Version 8.5 
–64– 
08/31/2016 
 
12. If you do not currently use other forms of tobacco, but did in the past, how long has it been since you last 
used other forms of tobacco regularly?  
 
 Within the past month (0 to 1 month ago) 
 Between 1 and 3 months (1 to 3 months ago) 
 Between 3 and 6 months (3 to 6 months ago) 
 Between 6 and 12 months (6 to 12 months ago) 
 Between 1 and 5 years (1 to 5 years ago) 
 Between 5 and 15 years (5 to 15 years ago) 
 More than 15 years ago 
 Don’t know/Not sure 
 Never used other forms of tobacco regularly 
 
Section C. Second-Hand Smoke Exposure 
 
13. Are you currently living with a smoker?   
 
Yes 
 
 No  
 
14. In the past 30 days, have you lived in a place where other people smoked cigarettes indoors?  
 
Yes 
 
 No  
 
15. In the past 30 days, have you worked in a place where other people smoked cigarettes indoors? 
 
Yes 
 
 No  
 
16. Thinking of all your childhood and adult years, have you ever lived in a place where other people smoked 
cigarettes indoors? 
 
 Yes 
In total, for about how many years?_______ If less than 1, write “1.”   
 No  
 
17. Thinking of all the years you have worked, have you ever worked in a place where other people smoked 
cigarettes indoors?    
 
Yes 
→ In total, for about how many years?_______ If less than 1, write “1.”    
 No 
 
Signature of Individual Completing This Form___________________   Date  __ __ / __ __ / __ __ __ __ 
 
(MM/DD/YYYY) 
Name of Individual Completing This Form (please print) ______________________________________ 
 
 

DCP Protocol Number MDA2016-08-02 
Protocol Version 14, Dated 4/27/2021 
 
DCP Protocol Template Version 8.5 
–65– 
08/31/2016 
 
APPENDIX E 
 
Alcohol and Tobacco Use Assessment Questionnaires – Follow Up 
 
 
 

DCP Protocol Number MDA2016-08-02 
Protocol Version 14, Dated 4/27/2021 
 
DCP Protocol Template Version 8.5 
–66– 
08/31/2016 
 
ALCOHOL ASSESSMENT – FOLLOW UP 
 
REGISTERING INSTITUTION 
 
_________________________ 
PARTICIPANT ID 
 
_________________ 
VISIT TYPE 
 
________________ 
VISIT DATE 
(MM/DD/YYYY) 
___ ___ / ___ ___ / ___ ___ ___ ___ 
 
Instructions: 
 
For the following questions about drinking alcoholic beverages, a drink means a 12 oz. beer, a 5 oz. 
glass of wine, or one and a half ounces of liquor. 
 
1. During the past 30 days, did you drink any alcoholic beverages?  
 
 Yes 
 No (End) 
 Refused (End) 
 Don’t know/Not sure 
 
2. During the past 30 days, how many days per week or per month did you drink any alcoholic beverages, on 
the average?  
 
________ (Enter number of days you drank based on the timeframe checked below.  Enter 0 if you did 
not drink.)  
 
 Week  
 Month 
 Refused 
 Don’t know/Not sure 
 
3. On the days when you drank, on average, about how many drinks did you have?  
 
________ (Enter the average number of drinks you had per day.) 
 
 Refused 
 Don’t know/Not sure 
 
4. In the past 30 days, on how many days did you have 5 or more drinks per day?  
 
_____________Number of times 
 
 None  
 Do not know/Not sure 
 
 
Signature of Individual Completing This Form___________________   Date  __ __ / __ __ / __ __ __ __ 
 
(MM/DD/YYYY) 
Name of Individual Completing This Form (please print) ______________________________________ 
 
 

DCP Protocol Number MDA2016-08-02 
Protocol Version 14, Dated 4/27/2021 
 
DCP Protocol Template Version 8.5 
–67– 
08/31/2016 
 
TOBACCO ASSESSMENT – FOLLOW UP 
 
REGISTERING INSTITUTION 
 
_________________________ 
PARTICIPANT ID 
 
_________________ 
VISIT TYPE 
 
________________ 
VISIT DATE 
(MM/DD/YYYY) 
___ ___ / ___ ___ / ___ ___ ___ ___ 
 
1. Do you NOW smoke cigarettes?  
 
 Everyday 
 Some days 
 Not at all → Skip to Question 3. 
 
2. On average, when you smoked, about how many cigarettes do you (or did you) smoke a day? (A pack 
usually has 20 cigarettes in it).    
 
_____ Number of cigarettes per day 
 
3. How long has it been since you last smoked a cigarette (even one or two puffs)?    
 
First check which one of the following choices applies to you. Then, if applicable, write a number on the 
line  
for how many days, weeks, months, or years it has been since your last cigarette. 
 
 I smoked a cigarette today (at least one puff) 
 1-7 days → Number of days since last cigarette ________ 
 Less than 1 month → Number of weeks since last cigarette _________ 
 Less than 1 year → Number of months since last cigarette __________ 
 More than 1 year → Number of years since last cigarette ___________ 
 Don’t know/Don’t remember 
 
4. Since your last visit, have you used other forms of tobacco, not including cigarettes?  
 
 Yes 
  No (End) 
 
5. How often do you/did you use other forms of tobacco?  
 
 Every day → Number of times per day ________ 
 Some days → Number of days _______ per 
 Week 
 Month 
Year 
 
 
 
 
 
 
 

DCP Protocol Number MDA2016-08-02 
Protocol Version 14, Dated 4/27/2021 
 
DCP Protocol Template Version 8.5 
–68– 
08/31/2016 
 
6. Since your last visit, which of the following products have you used?  Check all that apply 
 
 Cigarettes 
 E-cigarettes or other electronic nicotine delivery system 
 Traditional cigars, cigarillos or filtered cigars 
 Pipes 
 Waterpipe 
 Hookah 
 Clove cigarettes or kreteks 
 Bidis  
 Smokeless tobacco, like dip, chew, or snuff 
 Snus 
 Paan with tobacco, gutka, zarda, khaini 
 Other, Specify____________________________________________________________________ 
 
7. If you do not currently use other forms of tobacco, but did in the past, how long has it been since you last 
used other forms of tobacco regularly?  
 
 Within the past month (0 to 1 month ago) 
 Between 1 and 3 months (1 to 3 months ago) 
 Between 3 and 6 months (3 to 6 months ago) 
 Between 6 and 12 months (6 to 12 months ago) 
 Between 1 and 5 years (1 to 5 years ago) 
 Between 5 and 15 years (5 to 15 years ago) 
 More than 15 years ago 
 Don’t know/Not sure 
 Never used other forms of tobacco regularly 
 
The following instructions pertain to questions 8 - 10.  During each of the following time frames, please 
indicate whether you smoked cigarettes every day, some days, or not at all. 
 
8.  During study treatment 
 
 Smoked every day 
 Smoked some days 
 Did not smoke at all 
 Don’t know/not sure 
 Not applicable  
 
9.  After the end of study treatment 
 
 
 Smoked every day 
 Smoked some days 
 Did not smoke at all 
 Don’t know/not sure 
 Not applicable (I have not completed the study treatment) 

DCP Protocol Number MDA2016-08-02 
Protocol Version 14, Dated 4/27/2021 
 
DCP Protocol Template Version 8.5 
–69– 
08/31/2016 
 
 
 
 
 
10.  Since your last visit to this clinic 
 
 
 Smoked every day 
 Smoked some days 
 Did not smoke at all 
 Don’t know/not sure 
 Not applicable (This is my first visit to this clinic) 
 
 
 
Signature of Individual Completing This Form___________________   Date  __ __ / __ __ / __ __ __ __ 
 
(MM/DD/YYYY) 
Name of Individual Completing This Form (please print) ______________________________________ 
 
 
 
 
 
 
 

DCP Protocol Number MDA2016-08-02 
Protocol Version 14, Dated 4/27/2021 
 
DCP Protocol Template Version 8.5 
–70– 
08/31/2016 
 
APPENDIX F 
 
Resources for tobacco and alcohol quitting 
 
 
 
 

DCP Protocol Number MDA2016-08-02 
Protocol Version 14, Dated 4/27/2021 
 
DCP Protocol Template Version 8.5 
–71– 
08/31/2016 
 
National and local resources to help with alcohol abuse and 
alcoholism 
NIAAA’s online guide Treatment for Alcohol Problems: Finding and Getting Help is written for 
individuals, and their family and friends, who are looking for options to address alcohol problems. It 
is intended as a resource to understand what treatment choices are available and what to consider 
when selecting among them. https://pubs.niaaa.nih.gov/publications/treatment/treatment.htm 
Other resources: 
National Institute on Alcohol Abuse and Alcoholism www.niaaa.nih.gov  
301–443–3860  
National Institute on Drug Abuse www.nida.nih.gov  
301–443–1124  
National Clearinghouse for Alcohol and Drug Information www.samhsa.gov  
1–800–729–6686  
Substance Abuse Treatment Facility Locator www.findtreatment.samhsa.gov  
1–800–662–HELP  
Alcoholics Anonymous (AA) www.aa.org  
212–870–3400 or check your local phone directory under “Alcoholism”  
Moderation Management www.moderation.org 
212–871–0974  
Secular Organizations for Sobriety www.sossobriety.org  
323–666–4295  
SMART Recovery www.smartrecovery.org  
440–951–5357  
Women for Sobriety www.womenforsobriety.org  
215–536–8026  
Al-Anon Family Groups www.al-anon.alateen.org  
1–888–425–2666 for meetings  
Adult Children of Alcoholics  www.adultchildren.org 
310–534–1815  
 

DCP Protocol Number MDA2016-08-02 
Protocol Version 14, Dated 4/27/2021 
 
DCP Protocol Template Version 8.5 
–72– 
08/31/2016 
 
National and local resources to help with quitting smoking 
NCI’s Smokefree.gov offers science-driven tools, information, and support that has helped smokers 
quit. You will find state and national resources, free materials, and quitting advice from NCI. 
Smokefree.gov was established by the Tobacco Control Research Branch of NCI, a component of 
the National Institutes of Health, in collaboration with the Centers for Disease Control and 
Prevention and other organizations. 
Publications available from the Smokefree.gov Web site include the following: 
• 
Clearing the Air: Quit Smoking Today for smokers interested in quitting. 
• 
Clear Horizons for smokers over age 50. 
• 
Forever Free™  for smokers who have recently quit. 
• 
Forever Free for Baby and Me™, in English and Spanish, for pregnant smokers who have 
recently quit. 
• 
Pathways to Freedom: Winning the Fight Against Tobacco for African American smokers. 
NCI’s Smoking Quitline at 1–877–44U–QUIT (1–877–448–7848) offers a wide range of services, 
including individualized counseling, printed information, referrals to other resources, and recorded 
messages. Smoking cessation counselors are available to answer smoking-related questions in 
English or Spanish, Monday through Friday, 8:00 a.m. to 8:00 p.m., Eastern time. Smoking cessation 
counselors are also available through LiveHelp, an online instant messaging service. LiveHelp is 
available Monday through Friday, 8:00 a.m. to 11:00 p.m., Eastern time. 
Your state has a toll-free telephone quitline. Call 1–800–QUIT–NOW (1–800–784–8669) to get 
one-on-one help with quitting, support and coping strategies, and referrals to resources and local 
cessation programs. The toll-free number routes callers to state-run quitlines, which provide free 
cessation assistance and resource information to all tobacco users in the United States. This initiative 
was created by the Department of Health and Human Services. For more information about quitlines, 
speak to an expert on the Smokefree.gov Web site. 
 
 
 

DCP Protocol Number MDA2016-08-02 
Protocol Version 14, Dated 4/27/2021 
 
DCP Protocol Template Version 8.5 
–73– 
08/31/2016 
 
 
APPENDIX G  
 
Plain Language Guide for Assessing Skin Application AEs 
Utilize this guide for assessing Skin Application AEs during the Day 8 phone call and Day 15 and Day 28 
visits. To assess skin toxicity please ask the participant non-leading questions such as “Have you noted any 
changes in the skin of your breast?”  If the participant reports yes, then utilize the plain language guide below 
to ask more probing questions as needed. 
 
1. Is your breast skin dry from gel application? If yes, is it red or itchy?  
 
2. Do you have pain on your breast skin? If yes, how severe? 
 
3. Is your skin itchy from gel application? If yes, how severe? Are you taking any medicine for it? 
 
4. Do you have rash on your breast skin? If yes, how big is the affected area? Are you taking any 
medicine for it? Can you please send us a picture of your rash?  
 
5. Do you have hives on the breast skin where you have applied the gel? If yes, how big is the affected 
area? Are you taking any medicine for it?